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Abstract: MicroRNAs (miRNAs), a class of small non-coding RNA molecules, are responsible for
RNA silencing and post-transcriptional regulation of gene expression. They can mediate a fine-tuned
crosstalk among coding and non-coding RNA molecules sharing miRNA response elements (MREs).
In a suitable environment, both coding and non-coding RNA molecules can be targeted by the same
miRNAs and can indirectly regulate each other by competing for them. These RNAs, otherwise known
as competing endogenous RNAs (ceRNAs), lead to an additional post-transcriptional regulatory layer,
where non-coding RNAs can find new significance. The miRNA-mediated interplay among different
types of RNA molecules has been observed in many different contexts. The analyses of ceRNA
networks in cancer and other pathologies, as well as in other physiological conditions, provide new
opportunities for interpreting omics data for the field of personalized medicine. The development
of novel computational tools, providing putative predictions of ceRNA interactions, is a rapidly
growing field of interest. In this review, I discuss and present the current knowledge of the ceRNA
mechanism and its implications in a broad spectrum of different pathologies, such as cardiovascular
or autoimmune diseases, cancers and neurodegenerative disorders.
Keywords: competing endogenous RNAs; ceRNA mechanism; miRNA; non-coding RNAs; cancer;
cardiovascular pathologies; neurodegenerative disorders
1. Introduction
MicroRNAs (miRNAs) are found in protozoa, plants and animals [1], and are known for their
traditional role as post-transcriptional fine-tune regulators [2,3]; however, in the recent years, miRNAs
have been investigated and associated with playing a new regulatory level: as an information medium,
able to interact across the many different species of RNA molecules, establishing an elaborate dynamic
balance among transcriptional products [4].
1.1. RNA Molecules Landscape and their Classical Roles
A variety of RNA molecules has been subjected to meticulous classifications [5] and their growing
number subtypes, in particular, the class of coding and non-coding RNA with a potential regulatory
effect have been the subject of in-depth studies [6–8], as well as being the topic of many functional
annotation resources [9–12]. Beside the most famous RNA subtypes, such as coding messenger
RNAs (mRNAs), transfer RNAs (tRNAs) and ribosomal RNAs (rRNAs), recent research has taken a
particular interest in pseudo-genes (Ψ-genes), long non-coding RNAs (lncRNAs) and circular RNAs
(circRNAs) [6]. The non-coding elements have been shown to represent one of the largest portions of
transcribed molecules [12–15], and to be involved in a very broad set of biological processes [16–19],
cell-fate programming [20], aging [21,22] and diseases [23].
lncRNAs cooperate in gene regulation [17,24,25], from transcriptional and post-transcriptional
levels [26,27] to translational and post-translational commitments [28,29], up to epigenetic [30,31] and
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cell signaling modulation [32]. Ψ-genes, once considered “genomic fossils”, play a fundamental role
in the regulation of their cognate genes [33] and circRNAs, far from being considered experimental
artifacts, participate in transcriptional and post-transcriptional gene regulation of their parental genes
through interactions with specific spliceosomal components in the nucleus [34,35].
This list includes at least one other fundamental class: microRNAs (miRNAs). MicroRNAs are
a subtype of small non-coding RNA of about 20–22 nucleotides in length [36] and are produced
through an elaborate biogenesis process [3,37,38], starting from transcription in the nucleus until
cytoplasmic processing by the RNase III enzyme Dicer [39]. Mature miRNAs are integrated into the
RNA-induced silencing complex (RISC), a multiprotein complex, and guide it to target transcripts,
usually interfering with their translation and sometimes even promoting their degradation [40,41].
Target recognition is driven by a partial sequence complementarity mechanism based on a short
microRNA response element (MRE) sequence found on a transcript and the “seed” sequence on the
miRNA, a 6 to 8-nt sequence highly conserved across species. Interestingly, this regulation mechanism
is characterized by a high complexity for distinct miRNAs are able to modulate the expression of
more than one target transcript, and conversely, each transcript, harboring different MREs, may be
regulated by multiple miRNAs [2,42]. Even mutations that seem negligible can significantly affect this
mechanism—a change in the seed sequence may alter a specific miRNA target set and a change in an
MRE can free a target from the miRNA-modulation [40,43]. In particular, it was shown that non-coding
RNA (ncRNA) molecules, such as pseudo-genes, lncRNA and circRNA, represent a large reservoir of
putative miRNA targets, as they too harbor MREs and can thus be bound by mature miRNAs. This
specific ability of miRNAs to regulate various types of RNAs represents one of the most intriguing
discoveries and provides a possible explanation of many aspects of fine-tuned post-transcriptional
gene regulation [2,44].
1.2. Competing Endogenous RNA (ceRNA) Hypothesis
Since miRNAs can recognize their target sites on different RNA molecules, it was suggested that
miRNAs could be capable of mediating a regulatory crosstalk between the various components of
the transcriptome. This miRNA regulation should be modulated by other RNA molecules, as both
mRNAs and non-coding RNAs are known to be bound by miRNA and to be significantly expressed
in many different biological conditions. This mechanism offers an additional post-transcriptional
gene regulation mechanism and a complementary point of view for the role of the large number of
transcribed, but not translated, RNAs (see Figure 1) [4].
When two or more RNAs share common miRNA response elements (MREs) (mostly on their 3’
untranslated region (3’UTR), in the case of mRNAs) they can be targeted by the same microRNA(s),
implying that they can cross-regulate each other indirectly because they compete to bind the same
pool of sequences (see Figure 2) [4,45].
For instance, we can consider a very simple and naive situation composed of one miRNA: miR-A,
and one target: transcript-X harboring one MRE per molecule. In a 1:2 proportion ratio at the steady
state, 50% of the transcript-X molecules are not affected by miR-A control. If a new miR-A target
(transcript-Y) is added, with the same MRE per molecule and in the same amount as transcript-X,
the new ratio between miR-A and transcript-X will be 1:4, leading to an average of 75% of transcript-X
molecules being free from miRNA regulation without any changes in the transcriptional rate of
transcript-X (see Figure 3).
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Figure 1. Transcription and post-transcription regulation of messenger RNAs (mRNAs) can be affected
by several direct and indirect mechanisms involving circular RNAs (circRNAs), pseudo-genes (Ψ-genes)
and long non-coding RNAs (lncRNAs). Some of these processes act on the transcription rate in the
nucleus through the specific RNA–RNA complex, some others help the stability of mRNA molecules in
the cytoplasm. Alongside this, the competing endogenous RNA (ceRNA) mechanism offers a parallel
and complementary way through the same actors, protein coding and non-coding RNAs, but instead
mediated by microRNAs (miRNAs).
Figure 2. Left panel: A naive situation with one miRNA: miR-A, and one target: transcript-X.
Transcript-X harbors miR-A microRNA response elements (MREs) and can be post-transcriptionally
regulated by miR-A. Right panel: In the same situation, a new miR-A target is added, transcript-Y.
Transcript-Y harbors itself miR-A MREs and can sponge miR-A, thus leading to a reduced
post-transcriptional regulation of transcript-X by miR-A through an indirect crosstalk.
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Figure 3. Top left panel: Before interaction, a naive situation with one miRNA: miR-A, and one target:
transcript-X, in a 1:2 proportion ratio. Transcript-X harbors one miRNA response element (MRE) per
molecule. Bottom left panel: After interaction, at the steady state, 50% of transcript-X molecules
are under the miRNA repressive action (whether post-transcriptional degradation or translational
repression) and 50% of transcript-X molecules are not affected by miR-A control. Top right panel:
Before interaction, a new miR-A target is added: transcript-Y, in the same amount of transcript-X.
Transcript-Y also has the same MRE per molecule. The new ratio between miR-A and transcript-X is 1:4.
Bottom right panel: After interaction, at the steady state, miRNAs are shared in the same proportion
between the two transcripts’ molecules. On average, 75% of transcript-X molecules are free from
miRNA regulation without any changes in the transcriptional rate of transcript-X.
In general, in this new approach, transcripts could actively communicate among them, regulating
their respective expression levels through a specific language in which letters are coded into the
MREs. This mechanism enlarges the number of 3’UTR regulatory possibilities—they regulate
the expression of the encoded proteins acting in -cis and could modulate the abundance of
other transcripts in -trans by sequestering miRNA molecules. The same mechanism extends to
gene regulation network relationships, adding a novel layer of indirect interactions [42,46–48].
The competing endogenous RNAs (ceRNAs) mechanism provides a potential explanation of some of
the unexpected effects elicited by highly up- or down-regulation [4,49–51]. Strong down-regulation
of an miRNA-modulated transcript can release a large number of miRNA molecules, which would
become free to bind to other target transcripts and hyper-repress them. Conversely, overexpression
of an miRNA-modulated transcript can sequester a higher number of miRNA molecules, thus
de-repressing other target transcripts.
Several in silico prediction strategies were devised as a corollary of the new ceRNA logic.
Transcripts acting as ceRNA should show a correlated expression trend among themselves and
an anticorrelated tendency with the miRNAs they compete with [49,52–54]. A fundamental step is
represented by the predictions of miRNA-transcript interactions. In silico models rely mostly on the
analysis of seed matching sequences and thermodynamic constraints (interacting free energy and RNAs
secondary structures) [55,56] whereas other techniques, like those based on CLASH (crosslinking,
ligation and sequencing of hybrids) or CLIP (crosslinking and immunoprecipitation) strategies, provide
new evidence of non-canonical binding sites, enlarging and better specifying the miRNA-targets
landscape [57–60]. ceRNA interaction databases combine differential expression and co-expression
considerations of the putative long- and short-RNA players, and provide a scoring system based on the
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number of shared miRNAs, reflecting the assumption—the more common miRNAs transcripts share,
the stronger their reciprocal modulation [52,61–65]. Alongside other ceRNA bioinformatic inferring
packages [66–68], other in vitro and in vivo experimental evidence [50,69] was produced to support
this additional layer of post-transcriptional regulation; this evidence simultaneously appeared both
immediately captivating and highly disputed.
Doubt was raised by considering the effective stoichiometric tolerance of RNA molecules and the
extent of this mechanism in the cell life, from physiological, pathological and aberrant contexts. In this
respect, different mathematical models were proposed in order to demonstrate, at least in principle,
the feasibility of this mechanism [42,70,71]. The predictions offered by these mathematical models
revealed that ceRNA-mediated cross-regulation depends on several factors. The absolute and relative
abundance of RNA molecules, miRNAs-ceRNAs binding affinity and the number of MREs are among
the most relevant. According to mathematical results, optimal conditions for ceRNA activity are
reached when the number of seeds for an miR-family and its MREs are near equimolarity [42]. In such
an environment, a small change in one or few transcript expression levels would greatly influence
those of its or their ceRNAs by increasing or decreasing the number of free miRNA molecules.
To consider the possibility and extent of the proposed ceRNAs molecular permissive context
in more depth, other biological models were paired with proper mathematical models [72–76].
This approach resulted in new criticisms and proposed new solutions. On the one hand, the abundance
of targets seems to produce a conceptual obstacle—since each target is typically responsible only
for a small fraction of the total MREs pool, it is unlikely that a variation in the expression of one of
them can affect the others’ through a ceRNAs effect [72]. On the other hand, the emphasis on MREs’
hierarchical binding seems to open new perspectives: when miRNAs are expressed at a medium
range and the miRNAs:targets ratio is low, we see that miRNAs are likely to bind to high-affinity
sites (from 8mers to 6mers, according to TargetScan [55] seed classification). These “high-affinity”
targets are shown to be more responsive to ceRNAs crosstalk and, whether the number of miRNA
molecules and “high-affinity” targets verges on equimolarity, ceRNA crosstalk can be triggered by
a relatively small number of additional targets [73]. It must however be stressed that non-canonical
miRNA-target association sites, with their possible relevancy, function both in repression activity
and competition. Previously described techniques [57–60] allow for the detection of non-canonical
miRNA-target association sites even if the difficulty in knowing their precise extent only partially
grants their use in mathematical models [73,74].
Alongside the first protein-coding genes ceRNA networks and lncRNA-ceRNA interactions,
the growing availability of circRNAs sequences and expression data allows us to add them to the
ceRNA regulatory molecules repertoire. This class of RNA has been identified since the mid-1980s,
as a result of a specific type of exon scrambling, where a downstream splice donor site of an exon
meets an upstream splice acceptor site [77], but it is the use of high-throughput sequencing techniques
and specific alignment algorithms that have highlighted the widespread presence of these molecules
in cell systems and made their systematic characterization possible [78,79]. circRNAs show cell- and
tissue-specificity expression profiles, together with high expression levels, supporting their relevance
in biological functions [35]. They are particularly effective as sponges because they harbor a high
number of MREs [80] and exhibit an important characteristic as stable regulators—their enduring
lifetime. circRNAs are less exposed to degradation driven by exonucleases because they lack a
polyadenylated tail and show a median half-life 2.5 times longer than the median half-life of their
linear counterparts [81]. In this respect, circRNAs are more likely to be useful as sponges and to enter
into ceRNA circuitry than “linear” molecules [82].
Ever since this hypothesis was suggested, the number of papers containing references
to competing endogenous RNAs is constantly growing, demonstrating that this new and
indirect regulatory mechanism has made its way into the already rich panorama of biological
schemes [45,83–85].
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2. ceRNA and Diseases
Instances of ceRNA crosstalk were experimentally tested in a very large number of contexts
and were observed in both normal and pathological backgrounds, demonstrating the wide spread
proliferation of the mechanism. In particular, researchers collected evidence from normal physiology,
for instance in brain architecture [86] and regeneration mechanisms [87], neuronal and muscle
developmental processes [50,88], cellular differentiation [89] and reprogramming [90,91] and from
the immense landscape of diseases, syndromes and disorders where highly complex gene regulation
circuits are most affected by perturbations. Researchers work hard to model these regulatory networks
in order to predict and understand how modifications could alter the dynamic balance among
molecules, causing illness such as the onset of cancer and its progression, cardiovascular problems
and neurodegenerative disorders and other pathologies, such as those relating to the immune and
autoimmune response and to degenerative physical condition.
2.1. ceRNA and Cardiovascular Problems
Cardiovascular diseases are the leading causes of death worldwide. The aberrant balances
of coding and non-coding RNA molecules are often a reflection of, or the cause of the high
complexity of cardiovascular pathologies—from cardiac ischemia to cardiac fibrosis, from pathological
cardiac hypertrophy to blood vessels deficiencies. Many miRNAs are related to cardiogenesis,
heart development and heart normal functioning [92]: muscle-specific microRNAs (myomiRs) like
miR-1 and miR-133a are involved in embryonic stem cell development and cardiac-specific muscle
lineage commitment, whereas miR-208 and miR-499 collaborate to differentiate cardioblasts into
cardiomyocytes and to properly specify fast and slow muscle fiber by regulating the expression of
sarcomeric contractile proteins. miRNAs were proposed as potential therapeutic targets [93], but a
global understanding of ncRNAs is necessary.
Some ncRNAs-miRNAs-mRNAs networks were analyzed, leading to the discovery of numerous
lncRNAs functional modules in heart failure [94] and in cardiac hypertrophy (CH), involving important
oncogenic and well-characterized disease-related lncRNAs, such as HOX transcript antisense intergenic
RNA (HOTAIR) [95] or myocardial infarction and associated transcript (MIAT) [96,97]. Specifically
in CH, the crucial role of three new characterized lncRNAs (SLC26A4-AS1, RP11-344E13.3 and
MAGI1-IT) was proven [98] by combining miRNA-transcript interactions, expression data of cardiac
hypertrophy from an expressly re-annotated gene expression dataset, publicly available on Gene
Expression Omnibus (GEO, a public functional genomics data repository), and an analysis of the
most important network topological features like the degree, betweenness and closeness. Studies
on cardiomyocytes highlighted the role of miR-489 and of its target Myd88 (myeloid differentiation
primary response gene 88). miR-489 was found down-modulated in a microarray study conducted to
investigate miRNA differential expression in response to angiotensin II treatment. Further, in vitro
studies revealed miR-489 involvement in cardiomyocyte hypertrophy—its knockdown by antagomiRs
promoted cardiomyocyte hypertrophy and its overexpression resulted in the reduction of hypertrophic
responses. Among the different miR-489 target genes, Myd88 was already involved in cardiomyocyte
hypertrophy. In an experimental setting regarding angiotensin II treatment, miRNA expression changes
were shown to impact the expression of the target gene and on the observable hypertrophic phenotype,
revealing a functional relationship between miR-489 and Myd88 in hypertrophy. The same angiotensin
II treatment perturbation shows a time-dependent up-regulation of cardiac hypertrophy related factor
(CHRF) lncRNA levels. This lncRNA is able to directly bind to miR-489 and, under this pathological
condition, regulates hypertrophy by impacting on miR-489 activity and, indirectly, on Myd88 expression
(see Table 1) [99].
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Table 1. Table summarizing the miRNA-ceRNAs networks discussed in the review. Table fields are:
mRNA, protein coding genes name; ncRNA, non-coding RNAs class and name; miRNA, microRNA
involved; Disease; Reference. (a) HBMEC, Human Brain Microvascular Endothelial Cells; (b) SCA7,
Spinocerebellar Ataxia Type 7; (c) ARDS, Acute Respiratory Distress Syndrome; (d) PCOS, Polycystic
Ovary Syndrome; (e) CMEC, Cerebral Microvascular Endothelial Cell Injury.
mRNA ncRNA miRNA Disease Reference
Myd88 lncRNA—CHRF miR-489 Cardiac Hyperthrophy [99]
Akt3 lncRNA—CHRF miR-93 Cardiac Hyperthrophy [100,101]
TRL4 lncRNA—MIAT miR-93 Cardiac Hyperthrophy [97]
PTEN lncRNA—HOTAIR miR-19 Cardiac Hyperthrophy [95]
ATG7 lncRNA—APF miR-188-3p Cardiac Autophagy [102]
PTAFR lncRNA—PFL let-7d Cardiac Fibrosis [103]
TGF-beta pathway circ-0011565 let-7d Cardiac Fibrosis [104]
TGF-beta pathway circ-0010678 let-7d Cardiac Fibrosis [104]
TGF-beta pathway circ-0010219 let-7d Cardiac Fibrosis [104]
TGF-beta1 circRNA-010567 miR-141 Cardiac Fibrosis [105]
Col1a2 circRNA-000203 miR-26b-5p Cardiac Fibrosis [106]
CTGF circRNA-000203 miR-26b-5p Cardiac Fibrosis [106]
COL1A1 circHIPK3 miR-29b-3p Cardiac Fibrosis [107]
COL1A3 circHIPK3 miR-29b-3p Cardiac Fibrosis [107]
Alpha-SMA circHIPK3 miR-29b-3p Cardiac Fibrosis [107]
DAPK2 lncRNA—MIAT miR-22-3p Diabetic Cardiomyopathy [108]
SOX7 lncRNA—XIST miR-485-3p HBMEC (a) [109]
Atxn7 retro-Ψ-gene—lnc-SCA7 miR-124 SCA7 (b) [110]
BACE1 lncRNA—BACE1-AS miR-485-5p Alzheimer’s Disease [111,112]
VEGF lncRNA—MIAT miR-150-5p Alzheimer’s Disease [113]
HMGB1 lncRNA—MIAT miR-204-5p CMEC (e) [84]
IRF2 lncRNA—XIST miR-204 ARDS (c) [114]
TMEM120B lncRNA—PWRN2 miR-92b-3p PCOS (d) [115]
VEGF lncRNA—MIAT miR-150-5p Diabetes Mellitus [116]
BRAF Ψ-gene—Ψ-BRAF miR-134; miR-543; miR-653 Diffuse Large B Cell Lymphoma [69]
OCT4 Ψ-gene—OCT4-pg4 miR-145 Hepatocellular Carcinoma [117]
OCT4 Ψ-gene—OCT4-pg5 miR-145 Endometrial Carcinoma [118]
C-Myc pathway lncRNA—HOTAIR miR-130a Gallbladder Cancer [119]
HER2 lncRNA—HOTAIR miR-331-3p Gastric Cancer [120]
Derlin1 lncRNA—MIAT miR-132 Colorectal Cancer [121]
LASP1 lncRNA—MIAT miR-324-3p Papillary Thyroid Cancer [122]
PD-L1/CD274 lncRNA—MIAT miR-150-5p Immunotherapy Involvement [123]
Interestingly, the same CHRF lncRNA was shown to act in cardiac hypertrophy through the axis
miR-93-Akt [100]—the role of miR-93 (known to be involved in the progression of cardiac hypertrophy)
was analyzed in combination with the behavior of its direct target, CHRF lncRNA. Experiments
conducted in an isoproterenol induced-hypertrophy setting investigating cardiomyocytes showed
the increased CHRF expression and, conversely, the decreased miR-93 expression and suggested the
potential endogenous binding between miR-93 and its lncRNA target. miR-93 protein coding targets
were analyzed in order to identify a possible specific gene responsible for cardiac hypertrophy. Akt3
was selected as it was found in the overlap among the protein-coding genes putative miR-93 targets
and the PI3K/Akt signaling pathway—crucial regulators in the progression of cardiac hypertrophy.
The authors were able to demonstrate that the high-expression of CHRF can sponge miR-93 expression
and impact cardiac hypertrophy by altering Akt3 expression, even if pathway-specific regulatory
effects remain to be further elucidated [100,101].
Another study suggests the important role of lncRNA autophagy-promoting factor (APF) in
the molecular regulation of the autophagic program and myocardial infarction: in this biological
context, the translation of autophagy related 7 gene (ATG7), involved in ischemia/reperfusion-induced
myocardial injury, can be suppressed by miR-188-3p, an miRNA participating in autophagy inhibition
and cell death. APF lncRNA directly binds to and competes for miR-188-3p regulating ATG7 expression
and the consequent cardiac autophagy [102]. In specific myocardial infarction mouse models and in
fibrotic cardiac fibroblasts, another lncRNA was found related to cardiac dysfunctions—pro-fibrotic
(PFL) lncRNA inhibits the platelet-activating factor receptor (PTAFR) gene by competing for miR
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let-7d, and leads to fibrogenesis by increasing cell viability and promoting fibroblast-myofibroblast
transition [103]. The same let-7d miR represents a hub node in a specific ceRNA network based on
the high-throughput RNA sequencing data of cardiac fibroblasts from neonatal mice treated with
cardiac fibrosis (CF) induced by TGF-beta1. This miRNA is a key component of a module characterized
by cardiac fibrosis-related signaling pathways, like the transforming growth factor beta (TGF-beta)
signaling pathway and AMPK signaling pathway and some putative ceRNAs of it (novel-circ-0011565,
novel-circ-0010678 and novel-circ-0010219), found in the same module, may have a role in determining
the progression of this pathology [104]. In a similar signaling pathway, TGF-beta1 transcript is also
found to be regulated by miR-141 and, in a cardiac fibrosis context, this modulation is ceRNA-mediated
by circRNA-010567 [105]; the same CF models show how several fibrosis-related genes could be
under the regulatory effect of circ-ceRNA. In mouse CF models, circRNA-000203 was found to be
up-regulated, it sponged miR-26b-5p and it was able to suppress the interaction of miR-26b-5p with
Col1a2 and CTGF, to increase expression of Col1a2, Col3a1 and alpha-SMA genes and globally to
eliminate the antifibrotic effect of miR-26b in this pathology [106]. The same genes, alpha-SMA and
COL3A1, together with COL1A1, were found under the ceRNA regulation of circHIPK3 through the
action on miR-29b-3p. When overexpressed in vitro, circHIPK3 sponged miR-29b-3p and reversed the
miR-induced inhibition of cardiac fibroblasts proliferation and migration by altering the expression
levels of miR-29b-3p targeting genes (COL1A1, COL3A1 and alpha-SMA) [107].
Several other specific conditions, such as coronary artery disease and nonvalvular persistent atrial
fibrillation, have been associated with circRNAs, suggesting, respectively, that circ-YOD1 is a potential
biomarker [124] and that circRNA002085 and circRNA001321 show evidence of circRNA-associated
ceRNA mechanisms [125].
Furthermore, circRNAs and their paired miRNAs have been associated with
atherosclerosis [126,127] and myocardial infarction [128,129], cardiac hypertrophy [130,131]
and diabetic cardiomyopathy [106,132], aortic aneurysm [133] and ischemic heart disease [134,135] by
allowing the expansion of the interconnection of RNA molecules and pathways affected by different
pathologies [136].
2.2. ceRNA and Neurodegenerative Disorders
The understanding of ceRNA involvement in the broad spectrum of brain-related diseases has
increased dramatically in recent years.
Notably, one of the first discoveries of circRNA putative ceRNA involvement was found in
neuronal tissues. Characterized in a systematic screening of circRNAs in animals [80], the circRNA
CDR1as, antisense to the cerebellar degeneration-related protein 1 transcript, showed 74 MREs for
the highly conserved miR-7, 63 MREs, in particular, conserved in at least one species. CDR1as was
characterized by a stable and well detectable expression in the cytoplasm; in several brain regions, as in
mesencephalon, this circRNA showed significant co-expression with miR-7 and, moreover, was densely
bound by miRNA effector Argonaute (AGO) proteins. To further prove this post-transcriptional
regulation and support this competing balance, human and mouse CDR1as circular sequences were
injected into Danio rerio animal model embryos and the specific brain phenotype obtained was similar
to the phenotype caused by miR-7 knockdown.
Later on, ceRNAs crosstalk was associated with many facets of the biological processes involved
in the formation and functioning of the central nervous system, such as nerve injury repair in axon
regeneration through circ-Ankib1 action on different miRNAs in Schwann cells [137] or the proper
activity of human brain microvascular endothelial cells (HBMEC) where lncRNAs X-inactive specific
transcript (XIST), when down-modulated, impacts the vascular endothelial growth factor (VEGF)
signaling pathway by impairing hypoxia-induced angiogenesis via the miR-485-3p/SOX7 axis [109].
lncRNAs and circRNAs are crucial in numerous neurodegenerative pathologies too [138] and
evidence of RNAs balance disruption and ceRNA crosstalk was observed in Alzheimer’s and
Parkinson’s disease [139,140] and Spinocerebellar Ataxia Type 7 (SCA7). In particular, several
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lncRNAs are known to exhibit abnormal expression in several types of cancers and in brain disorders,
like lncRNA HOX transcript antisense intergenic RNA (HOTAIR) that exerts its regulatory roles in
cell apoptosis by sponging miR-221 in specific Parkinson’s disease cell lines [141], or in the same
context of Parkinson’s disease, like lncRNA MALAT1 (metastasis-associated lung adenocarcinoma
transcript 1), through its involvement in dendritic and synapse development. An investigation into
the role of MALAT1 in animal and in vitro models revealed its ceRNA function is linked to neuron
apoptosis through the sponge effect on miR-124 [142]. The same miR-124 characterizes the SCA7
pathology by mediating the interaction of lnc-SCA7 and Spinocerebellar Ataxia Type 7 Protein (Atxn7)
transcripts [110]. lnc-SCA7 is a retropseudogene highly conserved across mammals, its expression
positively correlates with that of ATXN7 in human and mouse adult tissues as well as in several central
nervous system areas. miR-124 MREs found both on the 3’UTRs of mouse lnc-SCA7 and Atxn7 suggests
the possibility of competing mechanisms between the two transcripts. This ceRNA post-transcriptional
regulation was proven by the observation that it is Dicer-dependent, among other evidence. lncRNA
knockdown caused a significant reduction of Atxn7 only in wild-type embryonic stem (ES) cells
whereas no significant reductions were observed in Dcr-deficient ES cells. This specific ceRNA
network can partially explain the selective neurodegeneration observed in SCA7. Although ATXN7 is
a ubiquitously expressed gene, miRNA-124 is most abundant in the retina and the cerebellum and
lnc-SCA7 shows a stronger correlation with ATXN7 in these same regions where the tissue-specific
pathology reveals itself.
An interesting example of a ceRNA complementary mechanism, which involves lncRNAs,
mRNAs and miRNAs, is found in Alzheimer’s disease (AD). The physiological expression of beta-site
amyloid precursor protein cleaving enzyme 1 (BACE1) is fundamental for several aspects of nerve
myelination [143] and synaptic functions [144]; however, elevated levels of the BACE1 protein are
linked to the formation of plaques through the generation of beta-amyloid peptides by the cleavage of
amyloid precursor protein [145]. lncRNA BACE1-AS, a conserved antisense transcript overlapping
BACE1 locus exhibits a concordant expression with BACE1 and, through the formation of a stabilizing
duplex with the BACE1 transcript, enhances the stability of BACE1 itself [146]. BACE1 harbor MREs
for miR-485-5p, although the potential miRNA-induced translational repression is inhibited by the
same transcripts duplex—BACE1-AS and miR-485-5p share a common binding site on the BACE1
transcript and the interaction of the two transcripts masks the MRE, thus preventing miR-485-5p action.
Dysregulation of this pair of miRNA and lncRNA, both found over-expressed in different regions of
AD brain tissues, may induce the up-regulation of BACE1 and consequently the onset of Alzheimer’s
disease [111,112].
2.3. An Increasing Spectrum of Different Pathologies Involved
In vitro studies, in silico predictions and in vivo models have shown that the ceRNA mechanism
is ubiquitous at a systemic level, as it could be detected in very different cellular phases and conditions.
Derived from patients’ indications, specific examples on ceRNA interactions emerge from a very broad
set of different syndromes.
lncRNA XIST, which is known to regulate X-chromosome inactivation by orchestrating the
right gene expression on the X chromosome in female mammals [147], and miR-204, involved in
arterial hypertension, diabetes, many cancer dysregulated pathways [148] but also fundamental in the
development of eyes and adipogenesis [149], are found to show competing crosstalk with interferon
regulatory factor 2 (IRF2) in lipo-polysaccharide-induced acute respiratory distress syndrome
(ARDS) [114] and polycystic ovary syndrome (PCOS). The abnormal up-regulation of Prader–Willi
region nonprotein coding RNA 2 (PWRN2) reduces the availability of hsa-miR-92b-3p and brings an
up-regulation of hsa-miR-92b-3p direct target—transmembrane protein 120B (TMEM120B) protein.
This up-regulation can promote adipocyte differentiation and, indirectly, cause spindle anomalies,
leading to abnormal oocyte development [115].
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Mutation of the LMNA gene can result in an accumulation in the nuclear membrane of progerin,
a specific splicing isoform of Lamin-A, causing Hutchinson–Gilford progeria syndrome. In order
to identify possible ceRNAs involved in this syndrome, several LMNA-predicted and validated
miRNAs were used, such as miR-9—involved in neurogenesis [150] and protective against the effects of
progeria [151], the tumor suppressor miR-34a [152] and miR-298 involved in Alzheimer’s disease [153].
In the top ranked list and based on the number of different shared miRNAs, key components of
the RNA interference machinery, like Dicer1, Argonaute and Drosha, are found together with genes
controlling the cell cycle, such as TP53 and CDKN1A, a result that enlarges the LMNA interactome and
suggests new interactions that could impinge on key cellular pathways [154].
ceRNAs hypothesis offers a conceptual framework to explain part of certain biological responses
in syndromes characterized by large chromosomal rearrangements [155], which is also observed
in certain tumor conditions. In the 5q-syndrome, bone marrow hematopoietic cells undergo the
loss of the 5q31.1 band, suffering a hematological disorder that could evolve into acute myeloid
leukemia. The simultaneous loss of many genes can impact the availability and abundance of a
specific set of microRNAs that subsequently may alter the activity of other target transcripts belonging
to other non-altered and apparently unrelated genomic regions. By miRNA–mRNA interaction
in silico analysis, nine miRNA (hsa-miR-3164, hsa-miR-513a-5p, hsa-miR-30c-1-3p, hsa-miR-1254,
hsa-miR-3916, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-4311 and hsa-miR-665) were identified and
used to pinpoint possible common target genes. To increase sensitivity and specificity, miRNAs targets
were crossed with the list of transcripts found dysregulated in a differential expression analysis based
on a similar syndrome in vitro setting composed by 5q- CD34+ cells compared to control CD34+ cells.
The filtered gene set was particularly interesting because it contained genes not yet associated with the
syndrome and two of the differentially-expressed transcripts, GRAMD1B and HIPK2, both target of all
nine miRNAs, were known to be already involved in other types of leukemia.
From inflammatory responses in diabetic nephropathy [156] and vascular endothelial cells
(VECs) [157] to the regulation of osteoarthritis progression [158,159] or in periodontitis [160,161],
many biological processes are found involved in the class of inflammatory mechanisms.
Several lncRNAs are found involved in miRNAs sponging activities as well in degenerative
mechanisms, like in for instance lumbar intervertebral disc degeneration [162] or in age-related
diseases (ARDs) where lncRNAs can affect many cellular homeostasis layers [163].
Interestingly, this competing mechanism also affects immune responses, such as in liver
cirrhosis [164] or in early HIV infection (EHI) gene expression regulatory networks [165] and it
participates in the regulation and evolution of deceitful autoimmune diseases like rheumatoid
arthritis [166,167].
2.4. ceRNA and Cancer
Last but not least, cancer was the first, and is one of the most studied, set of abnormalities
and dysfunction-causing disease where the ceRNA mechanism has been observed. From the very
beginning, every long RNA class has been associated with the ceRNA mechanism: Ψ-genes, together
with their mRNA related transcript [45,69]; lncRNAs with their pervasive presence [120,168,169];
circRNAs with their large number of MREs and longer lifetime [170,171]; protein-coding RNAs
themselves exhibiting coding independent functions [49].
Several new ncRNAs (both lncRNA and circRNA) are constantly highlighted through tissue- and
cell-specific next generation sequencing high-throughput experiments. Predictive gene regulatory
frameworks are fundamental to obtaining a high-confidence functional characterization of these
new molecules and to increasing the knowledge of the precise role of ncRNA. For instance, lncRNA
HOTAIR was characterized as one of the most important regulatory ncRNAs in human cells because
of its oncogenic role. It is located on chromosome 12q13.13 and transcribed from an antisense strand of
the HoxC gene [172]. HOTAIR was used as a prognostic biomarker for its role in the initiation and
progression of different tumor types and malignancies [119,173] and characterized for its ability
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to regulate gene expression, specifically to repress transcripts in the HOXD cluster, by binding
the polycomb repressive complex (PRC)2 and by recruiting (PRC)2 itself to the locus [174], or to
up-regulate SOX2 by epigenetically suppressing miR-34a and, in doing so, managing cell proliferation
regulation [175]. Alongside this application, HOTAIR was associated with a competing mechanism
in gallbladder cancer for its relationship with the c-Myc-activated pathway of malignancy and its
negative regulation of miRNA-130a [119] and in gastric cancer for its regulation of HER2 expression
by sponging miR-331-3p [120]. ceRNA crosstalk highlighted the regulatory role of HOTAIR on
the ceRNA-characterized tumor suppressor protein coding gene (PTEN) [45,49] but in the different
biological context of cardiac hypertrophy through its inhibitor activity of miR-19 [95].
In particular, specific in vitro and in vivo models were generated to experimentally validate
the involvement of Ψ-genes in ceRNA crosstalk. After the pioneering work showing that PTEN and
KRAS Ψ-genes are able to affect the levels of their cognate gene [45], the role of the BRAF Ψ-gene as
ceRNA was studied in an ad hoc tumorigenic system [69]. Several human cancers, including B cell
lymphomas, show aberrations of BRAFP1, both at genomic and transcriptional levels; Ψ-gene BRAFP1
acts as a ceRNA with BRAF in human cancer cell lines, where the silencing of BRAFP1 affects MAPK
signaling and cells proliferation; BRAFP1 mouse ortholog, BRAF-rs1, shows similar oncogenic activity
in in vitro settings. From these considerations, mouse models, able to mimic human diffuse large
B cell lymphoma, were engineered to overexpress murine BRAF Ψ-gene BRAF-rs1 and to follow its
putative activity as ceRNA. Three different and independent Dox-inducible settings were planned:
the overexpression of full-length Ψ-gene, its coding sequence and its 3’UTR. The oncogenic potential
of Ψ-BRAF was underlined by the need to have no supplementary engineered mutations to force the
onset of the phenotype and by the possibility to completely regress the tumor upon Dox withdrawal.
Ψ-BRAF molecules were sensitive to miRNA activity and able to sequester specific miRNA acting on
both BRAF and Ψ-BRAF, like miR-134, miR-543 and miR-653, leading to increased levels of BRAF when
Ψ-gene BRAF-rs1 overexpression was activated. Though with different severity, all three engineered
systems displayed a similar tumor phenotype supporting the hypothesis of an in vivo partial ceRNA
regulation of BRAF through BRAF-rs1.
In a large portion of tumor types, from the most diffuse types, such as breast, colorectal and lung
cancer, to the most rare types, such as head and neck squamous cell carcinoma or clear-cell renal cell
carcinoma, Ψ-genes have been found dysregulated and their aberrant expressions, up-regulation or
down-modulation, have been related to both oncogenic and tumor suppressor activities, respectively.
Although Ψ-genes and Ψ-gene-derived lncRNA can affect gene expression regulation through other
regulatory mechanisms, such as binding to transcription factors, several other ceRNA associations
were observed involving Ψ-genes and Ψ-gene-derived lncRNA, in human cancer, sharing MREs and
competing for common miRNAs with cognate or non-cognate genes [176].
OCT4, a key regulatory gene in the maintenance of stem cell pluripotency and proliferation,
was found overexpressed in multiple human tumors too. Interestingly, in these aberrant conditions,
miR-145 has been seen as a common mediator between OCT4 and two of its Ψ-genes, OCT4-pg4
and OCT4-pg5. Specifically, in hepatocarcinogenesis, the oncogenic role of OCT4-pg4, as a ceRNA,
emerges by preventing OCT4 transcript inhibition by decoying miR-145. In particular, OCT4-pg4
is located in chromosomal region 1q22, frequently amplified in hepatocellular carcinoma and this
Ψ-gene isoform, lacking the 3’UTR original region, harbors seed matches for miR-145 in the portion of
sequence deriving from the coding sequence of the parental OCT4. Its high expression in hepatocellular
carcinoma is able to sequester miR-145 molecules and, therefore, to de-repress OCT4 leading to the
coding gene aberrant high expression in this context [117]. Similarly, OCT4-pg5 is overexpressed in
endometrial cancer and shows a positive correlation with OCT4 high expression in the same tumor.
This Ψ-gene isoform can be directly targeted by miR-145 thanks to the MREs in the conserved 3’UTR
region, and its role in miR-145-mediated endometrial carcinoma cell proliferation emerges in the
regulation of OCT4 expression, by competing for miR-145, and of PI3K/AKT-cyclin D1 signaling
pathway [118].
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Tumors continue to highlight many new molecular mutations and cellular defects that affect
complex transcriptional and post-transcriptional balance [155,177] in almost all tissue-specific
gene regulation networks [178–184]. International consortia efforts, such as The Cancer Genome
Atlas (TCGA) [185], represent a huge step forward, and have collected and publicly shared the
data of transcripts and protein expression, sequences and genomic variants and other omics data.
Altogether, these efforts have made possible the transition from highly specific and context-dependent
ncRNA–miRNA–mRNA subsets to wide-ranging systems of biological studies characterized by a
much more general, complete and detailed set of regulatory networks [186–188].
3. Conclusions
This review traces a brief summary of the evolution of the ceRNA hypothesis and how the
scientific community has expanded its range of application. The ceRNA mechanism was found
to operate in a very broad set of biological contexts and almost all families of RNA molecules can
participate in these regulatory strategies.
Together with some experimental evidence in in vivo models, the vast majority of ceRNA
crosstalk is still predicted through in silico strategies and are shown to be effective in in vitro settings.
Bioinformatics predictions demand caution in the acceptance of these suggestions [114] deriving
from indirect biological evidence and statistical methods, but nevertheless, they demonstrate that
molecules can participate in this regulatory mechanism and, at the same time, offer a large number of
relationships that can be tested experimentally. The same miRNA identifiers used reflect the usage of
mixed experimental strategies, which require bioinformatics analysis and studies on animal models
and human cell lines. miRNAs are often indicated through their family name without specifying the
species prefix, reflecting their involvement in relationships that play an important role in different
species, demonstrating further the broad conservation of the action of the miRNAs themselves.
In particular, the importance of the ceRNA mechanism is related to its capacity to offer new
indications for diagnostic and prognostic putative biomarkers [94,189], targets for drugs such as
in hypertrophic scars treatment [190] and predictions for therapeutic strategies, such as in the cell
proliferation of complex mechanisms in regenerating livers [87,178], or as in the broad spectrum
of tumors [191–194] or still as in the pathogenesis of early HIV infection and its related antiviral
therapy [165].
Efforts spent in modeling ceRNA interactions and in exploring their most permissive molecular
environments [195] had the advantage of having contributed to the study and knowledge of the
molecules stoichiometry balance inside the cells and can further improve precision medicine associated
with the other most well known complex regulatory circuits (proteomics, metabolomics and more
general omics) [196,197].
At the same time, the organization of all the information already available, coming from thousands
of studies and spanning protein and RNA expression and co-expression networks, miRNAs target
prediction information, transcription factors activity, epigenetics and genomic topological knowledge
should be organized in order to allow for an easy expansion and integration with future studies and to
make immediately accessible the wealth of details and particularities that biological interconnections
offer at the level of different cells, tissues and organs contexts, stages of development and aging.
As well as dynamic and multipartite network approaches should be adopted to display information
and to browse across interactors, cellular contexts and diseases.
As a small and non-exhaustive example, lncRNA-myocardial infarction and associated transcript
(MIAT) was characterized in a large variety of conditions [198] (see Figure 4). As already mentioned
when discussing cardiac hypertrophy, MIAT has been found acting on at least two distinct miRNAs
in this abnormal enlargement and thickening of the heart muscle. miR-150, an important miRNA
involved in cardiac and cardiomyocyte hypertrophy, affects the development of cardiac hypertrophy as
a downstream effector of MIAT [96]. miR-93 differential abundance, mediated by lncRNA-MIAT,
influences the expression of target genes, as the highly conserved Toll-like receptor 4 (TLR4).
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In particular, MIAT knockdown can enhance miR-93 and inactivate the PI3K/Akt/mTOR pathway
via regulating the TLR4 in angiotensin II-induced cardiac hypertrophy [97]. MIAT works as a ceRNA
in pathological angiogenesis related to diabetes mellitus microvascular dysfunction, by competing
with vascular endothelial growth factor (VEGF) for miR-150-5p [116] and, following the same pathway,
in neurovascular dysfunction by inducing progressive neuronal loss and Alzheimer’s disease [113].
After cerebral ischemia, lncRNA-MIAT has proved to regulate the expression of HMGB1 (high-mobility
group box 1) in cerebral microvascular endothelial cell (CMEC) injury by competing for miR-204-5p [84].
The same lncRNA has been associated with diabetic cardiomyopathy (DCM) for it affects the expression
of death-associated protein kinase 2 (DAPK2) by sponging miR-22-3p: the resulting up-regulation
of DAPK2 itself leads to cardiomyocyte apoptosis in DCM [108]. Its involvements in cancer are
emerging too: in melanoma by acting on key master regulators of the signaling pathway [199];
in papillary thyroid cancer by sponging hsa-miR-324-3p and up-regulating LIM and SH3 domain
protein 1 (LASP1) [122]; in colorectal cancer by regulating the miR-132/Derlin-1 pathway [121]. New
observations have emerged in the control of immune checkpoint molecules: through hsa-miR-150-5p
sponge interaction, lncRNA-MIAT, together with HLA complex P5 (HCP5), has been associated with the
up-regulated expression of PD-L1/CD274, suggesting new involvements in the field of tumor immunity
and immunotherapy [123]. Independently from the ceRNA mechanism, the same lnc-RNA MIAT
molecules were characterized as oncogenic in esophageal cancer, as they promote cell invasion and
migration by interacting with histone methyltransferase mixed-lineage leukemia (MLL) proteins [200]
and, moreover, in gastric cancer, they have been linked to the prognosis and survival predictions: for
instance, high MIAT level in serum exosomal characterizes patients as more prone to develop gastric
cancer and its up-regulation is associated with shorter survival periods and represents an independent
prognostic factor for gastric cancer [201].
Figure 4. Partial representation of regulatory interaction of lnc-myocardial infarction and associated
transcript (MIAT): in ellipses, diseases are reported in bold and dysfunctions in italics; in comics,
interacting ceRNAs, or influenced transcripts, are reported in italics red and miRNAs in italics blue.
Different colors of ellipses are linked to different types of pathologies.
ceRNA crosstalk is widespread in many contexts and the integration of this mechanism with
all the other layers of gene regulation will guarantee new ways of increasing the understanding
of molecular and cellular mechanisms and to intervene in increasingly punctual and specific ways
in medicine.
Cells 2020, 9, 1574 14 of 23
Funding: This research did not receive any specific grant from funding agencies in the public, commercial or not
for profit sectors.
Acknowledgments: The author is grateful to Paolo Provero and Ferdinando Di Cunto for their proof-readings
and comments.
Conflicts of Interest: The author declares no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Bartel, D.P.; Chen, C.Z. Micromanagers of gene expression: The potentially widespread influence of
metazoan microRNAs. Nat. Rev. Genet. 2004, 5, 396–400. [CrossRef]
2. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215–233. [CrossRef]
[PubMed]
3. Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004, 116, 281–297. [CrossRef]
4. Salmena, L.; Poliseno, L.; Tay, Y.; Kats, L.; Pandolfi, P.P. A ceRNA hypothesis: The Rosetta Stone of a hid
RNA language? Cell 2011, 146, 353–358. [CrossRef] [PubMed]
5. Brosius, J.; Raabe, C.A. What is an RNA? A top layer for RNA classification. RNA Biol. 2016, 13, 140–144.
[CrossRef] [PubMed]
6. St Laurent, G.; Wahlestedt, C.; Kapranov, P. The Landscape of long noncoding RNA classification.
Trends Genet. 2015, 31, 239–251. [CrossRef]
7. Dahariya, S.; Paddibhatla, I.; Kumar, S.; Raghuwanshi, S.; Pallepati, A.; Gutti, R.K. Long non-coding RNA:
Classification, biogenesis and functions in blood cells. Mol. Immunol. 2019, 112, 82–92. [CrossRef]
8. Kopp, F.; Mendell, J.T. Functional Classification and Experimental Dissection of Long Noncoding RNAs.
Cell 2018, 172, 393–407. [CrossRef]
9. Kalvari, I.; Argasinska, J.; Quinones-Olvera, N.; Nawrocki, E.P.; Rivas, E.; Eddy, S.R.; Bateman, A.; Finn, R.D.;
Petrov, A.I. Rfam 13.0: Shifting to a genome-centric resource for non-coding RNA families. Nucleic Acids Res.
2018, 46, D335–D342. [CrossRef]
10. Kalvari, I.; Nawrocki, E.P.; Argasinska, J.; Quinones-Olvera, N.; Finn, R.D.; Bateman, A.; Petrov, A.I.
Non-Coding RNA Analysis Using the Rfam Database. Curr. Protoc. Bioinform. 2018, 62, e51. [CrossRef]
11. Chen, C.C.; Qian, X.; Yoon, B.J. RNAdetect: Efficient computational detection of novel non-coding RNAs.
Bioinformatics 2019, 35, 1133–1141. [CrossRef]
12. Uszczynska-Ratajczak, B.; Lagarde, J.; Frankish, A.; Guig, R.; Johnson, R. Towards a complete map of the
human long non-coding RNA transcriptome. Nat. Rev. Genet. 2018, 19, 535–548. [CrossRef] [PubMed]
13. Frankish, A.; Diekhans, M.; Ferreira, A.M.; Johnson, R.; Jungreis, I.; Loveland, J.; Mudge, J.M.; Sisu, C.;
Wright, J.; Armstrong, J.; et al. GENCODE reference annotation for the human and mouse genomes.
Nucleic Acids Res. 2019, 47, D766–D773. [CrossRef] [PubMed]
14. Fang, S.; Zhang, L.; Guo, J.; Niu, Y.; Wu, Y.; Li, H.; Zhao, L.; Li, X.; Teng, X.; Sun, X.; et al. NONCODEV5:
A comprehensive annotation database for long non-coding RNAs. Nucleic Acids Res. 2018, 46, D308–D314.
[CrossRef] [PubMed]
15. Iyer, M.K.; Niknafs, Y.S.; Malik, R.; Singhal, U.; Sahu, A.; Hosono, Y.; Barrette, T.R.; Prensner, J.R.; Evans, J.R.;
Zhao, S.; et al. The landscape of long noncoding RNAs in the human transcriptome. Nat. Genet. 2015,
47, 199–208. [CrossRef] [PubMed]
16. Pal, D.; Rao, M.R.S. Long Noncoding RNAs in Pluripotency of Stem Cells and Cell Fate Specification.
Adv. Exp. Med. Biol. 2017, 1008, 223–252.
17. Wang, K.C.; Chang, H.Y. Molecular mechanisms of long noncoding RNAs. Mol. Cell 2011, 43, 904–914.
[CrossRef]
18. Fatica, A.; Bozzoni, I. Long non-coding RNAs: New players in cell differentiation and development.
Nat. Rev. Genet. 2014, 15, 7–21. [CrossRef]
19. Zhang, N.; Meng, X.; Mei, L.; Hu, J.; Zhao, C.; Chen, W. The Long Non-Coding RNA SNHG1 Attenuates Cell
Apoptosis by Regulating miR-195 and BCL2-Like Protein 2 in Human Cardiomyocytes. Cell Physiol. Biochem.
2018, 50, 1029–1040. [CrossRef]
Cells 2020, 9, 1574 15 of 23
20. Flynn, R.A.; Chang, H.Y. Long noncoding RNAs in cell-fate programming and reprogramming. Cell Stem Cell
2014, 14, 752–761. [CrossRef]
21. Degirmenci, U.; Lei, S. Role of lncRNAs in Cellular Aging. Front. Endocrinol. (Lausanne) 2016, 7, 151.
[CrossRef] [PubMed]
22. Costa, M.C.; Leito, A.L.; Enguita, F.J. Noncoding Transcriptional Landscape in Human Aging. Curr. Top.
Microbiol. Immunol. 2016, 394, 177–202. [PubMed]
23. Jain, S.; Thakkar, N.; Chhatai, J.; Pal Bhadra, M.; Bhadra, U. Long non-coding RNA: Functional agent for
disease traits. RNA Biol. 2017, 14, 522–535. [CrossRef] [PubMed]
24. Mercer, T.R.; Dinger, M.E.; Mattick, J.S. Long non-coding RNAs: Insights into functions. Nat. Rev. Genet.
2009, 10, 155–159. [CrossRef] [PubMed]
25. Ulitsky, I.; Bartel, D.P. lincRNAs: Genomics, evolution, and mechanisms. Cell 2013, 154, 26–46. [CrossRef]
[PubMed]
26. Dykes, I.M.; Emanueli, C. Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding
RNA. Genom. Proteom. Bioinform. 2017, 15, 177–186. [CrossRef]
27. Huang, J.; Zhang, A.; Ho, T.T.; Zhang, Z.; Zhou, N.; Ding, X.; Zhang, X.; Xu, M.; Mo, Y.Y. Linc-RoR promotes
c-Myc expression through hnRNP I and AUF1. Nucleic Acids Res. 2016, 44, 3059–3069. [CrossRef]
28. Yoon, J.H.; Abdelmohsen, K.; Srikantan, S.; Yang, X.; Martindale, J.L.; De, S.; Huarte, M.; Zhan, M.;
Becker, K.G.; Gorospe, M. LincRNA-p21 suppresses target mRNA translation. Mol. Cell 2012, 47, 648–655.
[CrossRef]
29. Fernandes, J.C.R.; Acua, S.M.; Aoki, J.I.; Floeter-Winter, L.M.; Muxel, S.M. Long Non-Coding RNAs in the
Regulation of Gene Expression: Physiology and Disease. Noncoding RNA 2019, 5, 17. [CrossRef]
30. Yu, W.; Gius, D.; Onyango, P.; Muldoon-Jacobs, K.; Karp, J.; Feinberg, A.P.; Cui, H. Epigenetic silencing of
tumour suppressor gene p15 by its antisense RNA. Nature 2008, 451, 202–206. [CrossRef]
31. Meller, V.H.; Joshi, S.S.; Deshpande, N. Modulation of Chromatin by Noncoding RNA. Annu. Rev. Genet.
2015, 49, 673–695. [CrossRef] [PubMed]
32. Peng, W.X.; Koirala, P.; Mo, Y.Y. LncRNA-mediated regulation of cell signaling in cancer. Oncogene 2017,
36, 5661–5667. [CrossRef] [PubMed]
33. Tutar, Y. Pseudogenes. Comp. Funct. Genom. 2012, 2012, 424526. [CrossRef] [PubMed]
34. Li, Z.; Huang, C.; Bao, C.; Chen, L.; Lin, M.; Wang, X.; Zhong, G.; Yu, B.; Hu, W.; Dai, L.; et al.
Exon-intron circular RNAs regulate transcription in the nucleus. Nat. Struct. Mol. Biol. 2015, 22, 256–264.
[CrossRef] [PubMed]
35. Barrett, S.P.; Salzman, J. Circular RNAs: Analysis, expression and potential functions. Development 2016,
143, 1838–1847. [CrossRef] [PubMed]
36. Pu, M.; Chen, J.; Tao, Z.; Miao, L.; Qi, X.; Wang, Y.; Ren, J. Regulatory network of miRNA on its target:
Coordination between transcriptional and post-transcriptional regulation of gene expression. Cell. Mol.
Life Sci. 2019, 76, 441–451. [CrossRef]
37. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509–524. [CrossRef]
38. Khan, S.; Ayub, H.; Khan, T.; Wahid, F. MicroRNA biogenesis, gene silencing mechanisms and role in breast,
ovarian and prostate cancer. Biochimie 2019, 167, 12–24. [CrossRef]
39. Lund, E.; Dahlberg, J.E. Substrate selectivity of exportin 5 and Dicer in the biogenesis of microRNAs.
Cold Spring Harb. Symp. Quant. Biol. 2006, 71, 59–66. [CrossRef]
40. Cai, Y.; Yu, X.; Hu, S.; Yu, J. A brief review on the mechanisms of miRNA regulation.
Genom. Proteom. Bioinform. 2009, 7, 147–154. [CrossRef]
41. Catalanotto, C.; Cogoni, C.; Zardo, G. MicroRNA in Control of Gene Expression: An Overview of Nuclear
Functions. Int. J. Mol. Sci. 2016, 17, 1712. [CrossRef]
42. Ala, U.; Karreth, F.A.; Bosia, C.; Pagnani, A.; Taulli, R.; Leopold, V.; Tay, Y.; Provero, P.; Zecchina, R.;
Pandolfi, P.P. Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in
permissive molecular environments. Proc. Natl. Acad. Sci. USA 2013, 110, 7154–7159. [CrossRef]
43. Friedman, R.C.; Farh, K.K.; Burge, C.B.; Bartel, D.P. Most mammalian mRNAs are conserved targets of
microRNAs. Genome Res. 2009, 19, 92–105. [CrossRef] [PubMed]
44. Djuranovic, S.; Nahvi, A.; Green, R. miRNA-mediated gene silencing by translational repression followed
by mRNA deadenylation and decay. Science 2012, 336, 237–240. [CrossRef] [PubMed]
Cells 2020, 9, 1574 16 of 23
45. Poliseno, L.; Salmena, L.; Zhang, J.; Carver, B.; Haveman, W.J.; Pandolfi, P.P. A coding-independent function
of gene and pseudogene mRNAs regulates tumour biology. Nature 2010, 465, 1033–1038. [CrossRef]
[PubMed]
46. An, Y.; Furber, K.L.; Ji, S. Pseudogenes regulate parental gene expression via ceRNA network. J. Cell.
Mol. Med. 2017, 21, 185–192. [CrossRef]
47. Long, J.; Xiong, J.; Bai, Y.; Mao, J.; Lin, J.; Xu, W.; Zhang, H.; Chen, S.; Zhao, H. Construction and Investigation
of a lncRNA-Associated ceRNA Regulatory Network in Cholangiocarcinoma. Front. Oncol. 2019, 9, 649.
[CrossRef]
48. Zhang, Z.; Qian, W.; Wang, S.; Ji, D.; Wang, Q.; Li, J.; Peng, W.; Gu, J.; Hu, T.; Ji, B.; et al.
Analysis of lncRNA-Associated ceRNA Network Reveals Potential lncRNA Biomarkers in Human Colon
Adenocarcinoma. Cell. Physiol. Biochem. 2018, 49, 1778–1791. [CrossRef]
49. Tay, Y.; Kats, L.; Salmena, L.; Weiss, D.; Tan, S.M.; Ala, U.; Karreth, F.; Poliseno, L.; Provero, P.;
Di Cunto, F.; et al. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous
mRNAs. Cell 2011, 147, 344–357. [CrossRef]
50. Cesana, M.; Cacchiarelli, D.; Legnini, I.; Santini, T.; Sthandier, O.; Chinappi, M.; Tramontano, A.; Bozzoni, I.
A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA.
Cell 2011, 147, 358–369. [CrossRef]
51. Karreth, F.A.; Tay, Y.; Perna, D.; Ala, U.; Tan, S.M.; Rust, A.G.; DeNicola, G.; Webster, K.A.; Weiss, D.;
Perez-Mancera, P.A.; et al. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic
BRAF-induced mouse model of melanoma. Cell 2011, 147, 382–395. [CrossRef]
52. Sumazin, P.; Yang, X.; Chiu, H.S.; Chung, W.J.; Iyer, A.; Llobet-Navas, D.; Rajbhandari, P.; Bansal, M.;
Guarnieri, P.; Silva, J.; et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates
established oncogenic pathways in glioblastoma. Cell 2011, 147, 370–381. [CrossRef] [PubMed]
53. Karreth, F.A.; Ala, U.; Provero, P.; Pandolfi, P.P. Pseudogenes as competitive endogenous RNAs: Target
prediction and validation. Methods Mol. Biol. 2014, 1167, 199–212. [PubMed]
54. Chiu, H.S.; Llobet-Navas, D.; Yang, X.; Chung, W.J.; Ambesi-Impiombato, A.; Iyer, A.; Kim, H.R.;
Seviour, E.G.; Luo, Z.; Sehgal, V.; et al. Cupid: Simultaneous reconstruction of microRNA-target and
ceRNA networks. Genome Res. 2015, 25, 257–267. [CrossRef] [PubMed]
55. Agarwal, V.; Bell, G.W.; Nam, J.W.; Bartel, D.P. Predicting effective microRNA target sites in mammalian
mRNAs. Elife 2015, 4, e0500. [CrossRef] [PubMed]
56. Miranda, K.C.; Huynh, T.; Tay, Y.; Ang, Y.S.; Tam, W.L.; Thomson, A.M.; Lim, B.; Rigoutsos, I. A pattern-based
method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006,
126, 1203–1217. [CrossRef]
57. Helwak, A.; Kudla, G.; Dudnakova, T.; Tollervey, D. Mapping the human miRNA interactome by CLASH
reveals frequent noncanonical binding. Cell 2013, 153, 654–665. [CrossRef] [PubMed]
58. Chi, S.W.; Zang, J.B.; Mele, A.; Darnell, R.B. Argonaute HITS-CLIP decodes microRNA-mRNA
interaction maps. Nature 2009, 460, 479–486. [CrossRef] [PubMed]
59. Hamilton, M.P.; Rajapakshe, K.I.; Bader, D.A.; Cerne, J.Z.; Smith, E.A.; Coarfa, C.; Hartig, S.M.; McGuire, S.E.
The Landscape of microRNA Targeting in Prostate Cancer Defined by AGO-PAR-CLIP. Neoplasia 2016,
18, 356–370. [CrossRef] [PubMed]
60. Hafner, M.; Landthaler, M.; Burger, L.; Khorshid, M.; Hausser, J.; Berninger, P.; Rothballer, A.; Ascano, M.;
Jungkamp, A.C.; Munschauer, M.; et al. Transcriptome-wide identification of RNA-binding protein and
microRNA target sites by PAR-CLIP. Cell 2010, 141, 129–141. [CrossRef]
61. Sarver, A.L.; Subramanian, S. Competing endogenous RNA database. Bioinformation 2012, 8, 731–733.
[CrossRef] [PubMed]
62. Liu, K.; Yan, Z.; Li, Y.; Sun, Z. Linc2GO: A human LincRNA function annotation resource based on
ceRNA hypothesis. Bioinformatics 2013, 29, 2221–2222. [CrossRef] [PubMed]
63. Li, J.H.; Liu, S.; Zhou, H.; Qu, L.H.; Yang, J.H. starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and
protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014, 42, D92–D97.
[CrossRef] [PubMed]
64. Wang, P.; Zhi, H.; Zhang, Y.; Liu, Y.; Zhang, J.; Gao, Y.; Guo, M.; Ning, S.; Li, X. miRSponge: A manually
curated database for experimentally supported miRNA sponges and ceRNAs. Database (Oxford) 2015, 2015.
[CrossRef] [PubMed]
Cells 2020, 9, 1574 17 of 23
65. Wang, P.; Li, X.; Gao, Y.; Guo, Q.; Wang, Y.; Fang, Y.; Ma, X.; Zhi, H.; Zhou, D.; Shen, W.; et al.
LncACTdb 2.0: An updated database of experimentally supported ceRNA interactions curated from low-
and high-throughput experiments. Nucleic Acids Res. 2019, 47, D121–D127. [CrossRef]
66. Zhang, J.; Liu, L.; Xu, T.; Xie, Y.; Zhao, C.; Li, J.; Le, T.D. miRspongeR: An R-Bioconductor package for the
identification and analysis of miRNA sponge interaction networks and modules. BMC Bioinform. 2019,
20, 235. [CrossRef]
67. Mengying, Z.; Yongsheng, L.; Xu, J.; Li, X. CeRNASeek: Identification and Analysis of ceRNA Regulation.
2020. Available online: https://cran.r-project.org/web/packages/CeRNASeek/CeRNASeek.pdf (accessed
on 24 June 2020).
68. Junpeng, Z. miRSM: Inferring miRNA Sponge Modules by Integrating Expression Data and miRNA-Target
Binding Information. 2020. Available online: https://www.bioconductor.org/packages/devel/bioc/
vignettes/miRSM/inst/doc/miRSM.html (accessed on 24 June 2020).
69. Karreth, F.A.; Reschke, M.; Ruocco, A.; Ng, C.; Chapuy, B.; Lopold, V.; Sjoberg, M.; Keane, T.M.; Verma, A.;
Ala, U.; et al. The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma
in vivo. Cell 2015, 161, 319–332. [CrossRef] [PubMed]
70. Bosia, C.; Pagnani, A.; Zecchina, R. Modelling Competing Endogenous RNA Networks. PLoS ONE 2013,
8, e66609. [CrossRef]
71. Figliuzzi, M.; Marinari, E.; De Martino, A. MicroRNAs as a selective channel of communication between
competing RNAs: A steady-state theory. Biophys. J. 2013, 104, 1203–1213. [CrossRef]
72. Denzler, R.; Agarwal, V.; Stefano, J.; Bartel, D.P.; Stoffel, M. Assessing the ceRNA hypothesis with quantitative
measurements of miRNA and target abundance. Mol. Cell 2014, 54, 766–776. [CrossRef]
73. Bosson, A.D.; Zamudio, J.R.; Sharp, P.A. Endogenous miRNA and target concentrations determine
susceptibility to potential ceRNA competition. Mol. Cell 2014, 56, 347–359. [CrossRef] [PubMed]
74. Denzler, R.; McGeary, S.E.; Title, A.C.; Agarwal, V.; Bartel, D.P.; Stoffel, M. Impact of MicroRNA
Levels, Target-Site Complementarity, and Cooperativity on Competing Endogenous RNA-Regulated Gene
Expression. Mol. Cell 2016, 64, 565–579. [CrossRef] [PubMed]
75. Bosia, C.; Sgro, F.; Conti, L.; Baldassi, C.; Brusa, D.; Cavallo, F.; Cunto, F.D.; Turco, E.; Pagnani, A.;
Zecchina, R. RNAs competing for microRNAs mutually influence their fluctuations in a highly non-linear
microRNA-dependent manner in single cells. Genome Biol. 2017, 18, 37. [CrossRef] [PubMed]
76. Martirosyan, A.; Del Giudice, M.; Bena, C.E.; Pagnani, A.; Bosia, C.; De Martino, A. Kinetic Modelling of
Competition and Depletion of Shared miRNAs by Competing Endogenous RNAs. Methods Mol. Biol. 2019,
1912, 367–409. [PubMed]
77. Lasda, E.; Parker, R. Circular RNAs: Diversity of form and function. RNA 2014, 20, 1829–1842. [CrossRef]
[PubMed]
78. Qu, S.; Liu, Z.; Yang, X.; Zhou, J.; Yu, H.; Zhang, R.; Li, H. The emerging functions and roles of circular
RNAs in cancer. Cancer Lett. 2018, 414, 301–309. [CrossRef]
79. Salzman, J.; Gawad, C.; Wang, P.L.; Lacayo, N.; Brown, P.O. Circular RNAs are the predominant transcript
isoform from hundreds of human genes in diverse cell types. PLoS ONE 2012, 7, e30733. [CrossRef]
80. Memczak, S.; Jens, M.; Elefsinioti, A.; Torti, F.; Krueger, J.; Rybak, A.; Maier, L.; Mackowiak, S.D.;
Gregersen, L.H.; Munschauer, M.; et al. Circular RNAs are a large class of animal RNAs with regulatory
potency. Nature 2013, 495, 333–338. [CrossRef]
81. Enuka, Y.; Lauriola, M.; Feldman, M.E.; Sas-Chen, A.; Ulitsky, I.; Yarden, Y. Circular RNAs are long-lived and
display only minimal early alterations in response to a growth factor. Nucleic Acids Res. 2016, 44, 1370–1383.
[CrossRef]
82. Wilusz, J.E.; Sharp, P.A. Molecular biology. A circuitous route to noncoding RNA. Science 2013, 340, 440–441.
[CrossRef]
83. Salzman, J. Circular RNA Expression: Its Potential Regulation and Function. Trends Genet. 2016, 32, 309–316.
[CrossRef]
84. Deng, W.; Fan, C.; Shen, R.; Wu, Y.; Du, R.; Teng, J. Long noncoding MIAT acting as a ceRNA to sponge
microRNA-204-5p to participate in cerebral microvascular endothelial cell injury after cerebral ischemia
through regulating HMGB1. J. Cell. Physiol. 2020, 235, 4571–4586. [CrossRef]
85. Tay, Y.; Rinn, J.; Pandolfi, P.P. The multilayered complexity of ceRNA crosstalk and competition. Nature
2014, 505, 344–352. [CrossRef]
Cells 2020, 9, 1574 18 of 23
86. Cai, Y.; Sun, Z.; Jia, H.; Luo, H.; Ye, X.; Wu, Q.; Xiong, Y.; Zhang, W.; Wan, J. Rpph1 Upregulates CDC42
Expression and Promotes Hippocampal Neuron Dendritic Spine Formation by Competing with miR-330-5p.
Front. Mol. Neurosci. 2017, 10, 27. [CrossRef]
87. Wang, G.; Guo, X.; Cheng, L.; Chu, P.; Chen, M.; Chen, Y.; Chang, C. An integrated analysis of the
circRNA-miRNA-mRNA network reveals novel insights into potential mechanisms of cell proliferation
during liver regeneration. Artif. Cells Nanomed. Biotechnol. 2019, 47, 3873–3884. [CrossRef]
88. Valluy, J.; Bicker, S.; Aksoy-Aksel, A.; Lackinger, M.; Sumer, S.; Fiore, R.; Wst, T.; Seffer, D.; Metge, F.;
Dieterich, C.; et al. A coding-independent function of an alternative Ube3a transcript during neuronal
development. Nat. Neurosci. 2015, 18, 666–673. [CrossRef]
89. Yu, Y.; Chen, Y.; Zhang, X.; Lu, X.; Hong, J.; Guo, X.; Zhou, D. Knockdown of lncRNA KCNQ1OT1 suppresses
the adipogenic and osteogenic differentiation of tendon stem cell via downregulating miR-138 target genes
PPARgamma and RUNX2. Cell Cycle 2018, 17, 2374–2385. [CrossRef]
90. Zhang, X.; Zhang, J.; Zheng, K.; Zhang, H.; Pei, X.; Yin, Z.; Wen, D.; Kong, Q. Long noncoding RNAs sustain
high expression levels of exogenous octamer-binding protein 4 by sponging regulatory microRNAs during
cellular reprogramming. J. Biol. Chem. 2019, 294, 17863–17874. [CrossRef]
91. Chen, M.T.; Lin, H.S.; Shen, C.; Ma, Y.N.; Wang, F.; Zhao, H.L.; Yu, J.; Zhang, J.W. PU.1-Regulated Long
Noncoding RNA lnc-MC Controls Human Monocyte/Macrophage Differentiation through Interaction with
MicroRNA 199a-5p. Mol. Cell. Biol. 2015, 35, 3212–3224. [CrossRef]
92. Chistiakov, D.A.; Orekhov, A.N.; Bobryshev, Y.V. Cardiac-specific miRNA in cardiogenesis, heart function,
and cardiac pathology (with focus on myocardial infarction). J. Mol. Cell. Cardiol. 2016, 94, 107–121.
[CrossRef]
93. Bernardo, B.C.; Ooi, J.Y.; Lin, R.C.; McMullen, J.R. miRNA therapeutics: A new class of drugs with potential
therapeutic applications in the heart. Future Med. Chem. 2015, 7, 1771–1792. [CrossRef] [PubMed]
94. Fan, Z.; Gao, S.; Chen, Y.; Xu, B.; Yu, C.; Yue, M.; Tan, X. Integrative analysis of competing endogenous RNA
networks reveals the functional lncRNAs in heart failure. J. Cell. Mol. Med. 2018, 22, 4818–4829. [CrossRef]
95. Lai, Y.; He, S.; Ma, L.; Lin, H.; Ren, B.; Ma, J.; Zhu, X.; Zhuang, S. HOTAIR functions as a
competing endogenous RNA to regulate PTEN expression by inhibiting miR-19 in cardiac hypertrophy.
Mol. Cell. Biochem. 2017, 432, 179–187. [CrossRef] [PubMed]
96. Zhu, X.H.; Yuan, Y.X.; Rao, S.L.; Wang, P. LncRNA MIAT enhances cardiac hypertrophy partly through
sponging miR-150. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 3653–3660. [PubMed]
97. Li, Y.; Wang, J.; Sun, L.; Zhu, S. LncRNA myocardial infarction-associated transcript (MIAT) contributed to
cardiac hypertrophy by regulating TLR4 via miR-93. Eur. J. Pharmacol. 2018, 818, 508–517. [CrossRef]
98. Song, C.; Zhang, J.; Liu, Y.; Pan, H.; Qi, H.P.; Cao, Y.G.; Zhao, J.M.; Li, S.; Guo, J.; Sun, H.L.; et al. Construction
and analysis of cardiac hypertrophy-associated lncRNA-mRNA network based on competitive endogenous
RNA reveal functional lncRNAs in cardiac hypertrophy. Oncotarget 2016, 7, 10827–10840. [CrossRef]
[PubMed]
99. Wang, K.; Liu, F.; Zhou, L.Y.; Long, B.; Yuan, S.M.; Wang, Y.; Liu, C.Y.; Sun, T.; Zhang, X.J.; Li, P.F. The long
noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ. Res. 2014, 114, 1377–1388.
[CrossRef]
100. Wo, Y.; Guo, J.; Li, P.; Yang, H.; Wo, J. Long non-coding RNA CHRF facilitates cardiac hypertrophy through
regulating Akt3 via miR-93. Cardiovasc. Pathol. 2018, 35, 29–36. [CrossRef]
101. Heineke, J.; Molkentin, J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev.
Mol. Cell Biol. 2006, 7, 589–600. [CrossRef]
102. Wang, K.; Liu, C.Y.; Zhou, L.Y.; Wang, J.X.; Wang, M.; Zhao, B.; Zhao, W.K.; Xu, S.J.; Fan, L.H.; Zhang, X.J.; et al.
APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p. Nat. Commun. 2015,
6, 6779. [CrossRef]
103. Liang, H.; Pan, Z.; Zhao, X.; Liu, L.; Sun, J.; Su, X.; Xu, C.; Zhou, Y.; Zhao, D.; Xu, B.; et al. LncRNA
PFL contributes to cardiac fibrosis by acting as a competing endogenous RNA of let-7d. Theranostics 2018,
8, 1180–1194. [CrossRef] [PubMed]
104. Gu, X.; Jiang, Y.N.; Wang, W.J.; Zhang, J.; Shang, D.S.; Sun, C.B.; Tian, J.T.; Tian, J.W.; Yu, B.; Zhang, Y.
Comprehensive circRNA expression profile and construction of circRNA-related ceRNA network in
cardiac fibrosis. Biomed. Pharmacother. 2020, 125, 109944. [CrossRef]
Cells 2020, 9, 1574 19 of 23
105. Zhou, B.; Yu, J.W. A novel identified circular RNA, circRNA-010567, promotes myocardial fibrosis via
suppressing miR-141 by targeting TGF-beta1. Biochem. Biophys. Res. Commun. 2017, 487, 769–775. [CrossRef]
[PubMed]
106. Tang, C.M.; Zhang, M.; Huang, L.; Hu, Z.Q.; Zhu, J.N.; Xiao, Z.; Zhang, Z.; Lin, Q.X.; Zheng, X.L.;
Yang, M.; et al. CircRNA-000203 enhances the expression of fibrosis-associated genes by derepressing targets
of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts. Sci. Rep. 2017, 7, 40342. [CrossRef] [PubMed]
107. Ni, H.; Li, W.; Zhuge, Y.; Xu, S.; Wang, Y.; Chen, Y.; Shen, G.; Wang, F. Inhibition of circHIPK3 prevents
angiotensin II-induced cardiac fibrosis by sponging miR-29b-3p. Int. J. Cardiol. 2019, 292, 188–196. [CrossRef]
108. Zhou, X.; Zhang, W.; Jin, M.; Chen, J.; Xu, W.; Kong, X. lncRNA MIAT functions as a competing endogenous
RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy. Cell Death Dis. 2017,
8, e2929. [CrossRef]
109. Hu, C.; Bai, X.; Liu, C.; Hu, Z. Long noncoding RNA XIST participates hypoxia-induced angiogenesis in
human brain microvascular endothelial cells through regulating miR-485/SOX7 axis. Am. J. Transl. Res.
2019, 11, 6487–6497. [CrossRef]
110. Tan, J.Y.; Vance, K.W.; Varela, M.A.; Sirey, T.; Watson, L.M.; Curtis, H.J.; Marinello, M.; Alves, S.; Steinkraus, B.;
Cooper, S.; et al. Cross-talking noncoding RNAs contribute to cell-specific neurodegeneration in SCA7.
Nat. Struct. Mol. Biol. 2014, 21, 955–961. [CrossRef]
111. Faghihi, M.A.; Zhang, M.; Huang, J.; Modarresi, F.; Van der Brug, M.P.; Nalls, M.A.; Cookson, M.R.;
St-Laurent, G.; Wahlestedt, C. Evidence for natural antisense transcript-mediated inhibition of microRNA
function. Genome Biol. 2010, 11, R56. [CrossRef]
112. Roberts, T.C.; Morris, K.V.; Wood, M.J. The role of long non-coding RNAs in neurodevelopment, brain
function and neurological disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014, 369. [CrossRef]
113. Jiang, Q.; Shan, K.; Qun-Wang, X.; Zhou, R.M.; Yang, H.; Liu, C.; Li, Y.J.; Yao, J.; Li, X.M.; Shen, Y.; et al.
Long non-coding RNA-MIAT promotes neurovascular remodeling in the eye and brain. Oncotarget 2016,
7, 49688–49698. [CrossRef]
114. Wang, S.; Cao, F.; Gu, X.; Chen, J.; Xu, R.; Huang, Y.; Ying, L. LncRNA XIST, as a ceRNA of miR-204,
aggravates lipopolysaccharide-induced acute respiratory distress syndrome in mice by upregulating IRF2.
Int. J. Clin. Exp. Pathol. 2019, 12, 2425–2434.
115. Huang, X.; Pan, J.; Wu, B.; Teng, X. Construction and analysis of a lncRNA (PWRN2)-mediated ceRNA
network reveal its potential roles in oocyte nuclear maturation of patients with PCOS. Reprod. Biol. Endocrinol.
2018, 16, 73. [CrossRef]
116. Yan, B.; Yao, J.; Liu, J.Y.; Li, X.M.; Wang, X.Q.; Li, Y.J.; Tao, Z.F.; Song, Y.C.; Chen, Q.; Jiang, Q. lncRNA-MIAT
regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ. Res. 2015,
116, 1143–1156. [CrossRef]
117. Wang, L.; Guo, Z.Y.; Zhang, R.; Xin, B.; Chen, R.; Zhao, J.; Wang, T.; Wen, W.H.; Jia, L.T.; Yao, L.B.; et al.
Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing
for miR-145 in hepatocellular carcinoma. Carcinogenesis 2013, 34, 1773–1781. [CrossRef]
118. Bai, M.; Yuan, M.; Liao, H.; Chen, J.; Xie, B.; Yan, D.; Xi, X.; Xu, X.; Zhang, Z.; Feng, Y. OCT4 pseudogene 5
upregulates OCT4 expression to promote proliferation by competing with miR-145 in endometrial carcinoma.
Oncol. Rep. 2015, 33, 1745–1752. [CrossRef]
119. Ma, M.Z.; Li, C.X.; Zhang, Y.; Weng, M.Z.; Zhang, M.D.; Qin, Y.Y.; Gong, W.; Quan, Z.W. Long non-coding
RNA HOTAIR, a c-Myc activated driver of malignancy, negatively regulates miRNA-130a in gallbladder
cancer. Mol. Cancer 2014, 13, 156. [CrossRef]
120. Liu, X.H.; Sun, M.; Nie, F.Q.; Ge, Y.B.; Zhang, E.B.; Yin, D.D.; Kong, R.; Xia, R.; Lu, K.H.; Li, J.H.; et al.
Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging
miR-331-3p in gastric cancer. Mol. Cancer 2014, 13, 92. [CrossRef]
121. Liu, Z.; Wang, H.; Cai, H.; Hong, Y.; Li, Y.; Su, D.; Fan, Z. Long non-coding RNA MIAT promotes growth
and metastasis of colorectal cancer cells through regulation of miR-132/Derlin-1 pathway. Cancer Cell Int.
2018, 18, 59. [CrossRef]
122. Liu, W.; Wang, Z.; Wang, C.; Ai, Z. Long non-coding RNA MIAT promotes papillary thyroid cancer
progression through upregulating LASP1. Cancer Cell Int. 2019, 19, 194. [CrossRef]
123. Xu, S.; Wang, Q.; Kang, Y.; Liu, J.; Yin, Y.; Liu, L.; Wu, H.; Li, S.; Sui, S.; Shen, M.; et al. Long noncoding RNAs
control the modulation of immune checkpoint molecules in cancer. Cancer Immunol. Res. 2020. [CrossRef]
Cells 2020, 9, 1574 20 of 23
124. Miao, L.; Yin, R.X.; Zhang, Q.H.; Liao, P.J.; Wang, Y.; Nie, R.J.; Li, H. A novel circRNA-miRNA-mRNA
network identifies circ-YOD1 as a biomarker for coronary artery disease. Sci. Rep. 2019, 9, 18314. [CrossRef]
125. Zhang, Y.; Ke, X.; Liu, J.; Ma, X.; Liu, Y.; Liang, D.; Wang, L.; Guo, C.; Luo, Y. Characterization of circRNA
associated ceRNA networks in patients with nonvalvular persistent atrial fibrillation. Mol. Med. Rep. 2019,
19, 638–650. [CrossRef]
126. Mao, Y.Y.; Wang, J.Q.; Guo, X.X.; Bi, Y.; Wang, C.X. Circ-SATB2 upregulates STIM1 expression and
regulates vascular smooth muscle cell proliferation and differentiation through miR-939. Biochem. Biophys.
Res. Commun. 2018, 505, 119–125. [CrossRef]
127. Sun, J.; Zhang, Z.; Yang, S. Circ-RUSC2 upregulates the expression of miR-661 target gene SYK and regulates
the function of vascular smooth muscle cells. Biochem. Cell Biol. 2019, 97, 709–714. [CrossRef]
128. Wang, K.; Gan, T.Y.; Li, N.; Liu, C.Y.; Zhou, L.Y.; Gao, J.N.; Chen, C.; Yan, K.W.; Ponnusamy, M.; Zhang, Y.H.;
et al. Circular RNA mediates cardiomyocyte death via miRNA-dependent upregulation of MTP18 expression.
Cell Death Differ. 2017, 24, 1111–1120. [CrossRef]
129. Huang, S.; Li, X.; Zheng, H.; Si, X.; Li, B.; Wei, G.; Li, C.; Chen, Y.; Chen, Y.; Liao, W.; et al. Loss of
Super-Enhancer-Regulated circRNA Nfix Induces Cardiac Regeneration After Myocardial Infarction in
Adult Mice. Circulation 2019, 139, 2857–2876. [CrossRef]
130. Li, H.; Xu, J.D.; Fang, X.H.; Zhu, J.N.; Yang, J.; Pan, R.; Yuan, S.J.; Zeng, N.; Yang, Z.Z.; Yang, H.; et al.
Circular RNA circRNA-000203 aggravates cardiac hypertrophy via suppressing miR26b-5p and miR-140-3p
binding to Gata4. Cardiovasc. Res. 2019, 116, 1323–1334. [CrossRef]
131. Lim, T.B.; Aliwarga, E.; Luu, T.D.A.; Li, Y.P.; Ng, S.L.; Annadoray, L.; Sian, S.; Ackers-Johnson, M.A.; Foo, R.S.
Targeting the highly abundant circular RNA circSlc8a1 in cardiomyocytes attenuates pressure overload
induced hypertrophy. Cardiovasc. Res. 2019, 115, 1998–2007. [CrossRef]
132. Yang, F.; Li, A.; Qin, Y.; Che, H.; Wang, Y.; Lv, J.; Li, Y.; Li, H.; Yue, E.; Ding, X.; et al. A Novel Circular
RNA Mediates Pyroptosis of Diabetic Cardiomyopathy by Functioning as a Competing Endogenous RNA.
Mol. Ther. Nucleic Acids 2019, 17, 636–643. [CrossRef]
133. Zheng, C.; Niu, H.; Li, M.; Zhang, H.; Yang, Z.; Tian, L.; Wu, Z.; Li, D.; Chen, X. Cyclic RNA hsa-circ-000595
regulates apoptosis of aortic smooth muscle cells. Mol. Med. Rep. 2015, 12, 6656–6662. [CrossRef] [PubMed]
134. Li, M.; Ding, W.; Tariq, M.A.; Chang, W.; Zhang, X.; Xu, W.; Hou, L.; Wang, Y.; Wang, J. A circular transcript
of ncx1 gene mediates ischemic myocardial injury by targeting miR-133a-3p. Theranostics 2018, 8, 5855–5869.
[CrossRef]
135. Zhou, L.Y.; Zhai, M.; Huang, Y.; Xu, S.; An, T.; Wang, Y.H.; Zhang, R.C.; Liu, C.Y.; Dong, Y.H.; Wang, M.; et al.
The circular RNA ACR attenuates myocardial ischemia/reperfusion injury by suppressing autophagy via
modulation of the Pink1/FAM65B pathway. Cell Death Differ. 2019, 26, 1299–1315. [CrossRef]
136. Su, Q.; Lv, X. Revealing new landscape of cardiovascular disease through circular RNA-miRNA-mRNA axis.
Genomics 2020, 112, 1680–1685. [CrossRef] [PubMed]
137. Mao, S.; Zhang, S.; Zhou, S.; Huang, T.; Feng, W.; Gu, X.; Yu, B. A Schwann cell-enriched circular
RNA circ-Ankib1 regulates Schwann cell proliferation following peripheral nerve injury. FASEB J. 2019,
33, 12409–12424. [CrossRef] [PubMed]
138. Cai, Y.; Wan, J. Competing Endogenous RNA Regulations in Neurodegenerative Disorders: Current
Challenges and Emerging Insights. Front. Mol. Neurosci. 2018, 11, 370. [CrossRef] [PubMed]
139. Wang, L.K.; Chen, X.F.; He, D.D.; Li, Y.; Fu, J. Dissection of functional lncRNAs in Alzheimer’s disease
by construction and analysis of lncRNA-mRNA networks based on competitive endogenous RNAs.
Biochem. Biophys. Res. Commun. 2017, 485, 569–576. [CrossRef]
140. Zhang, S.; Zhu, D.; Li, H.; Li, H.; Feng, C.; Zhang, W. Characterization of circRNA-Associated-ceRNA
Networks in a Senescence-Accelerated Mouse Prone 8 Brain. Mol. Ther. 2017, 25, 2053–2061. [CrossRef]
141. Zhou, F.; Xie, S.; Li, J.; Duan, S. Long noncoding RNA HOTAIR promotes cell apoptosis by sponging miR-221
in Parkinson’s disease. RSC Adv. 2019, 9, 29502–29510. [CrossRef]
142. Liu, W.; Zhang, Q.; Zhang, J.; Pan, W.; Zhao, J.; Xu, Y. Long non-coding RNA MALAT1 contributes to cell
apoptosis by sponging miR-124 in Parkinson disease. Cell Biosci. 2017, 7, 19. [CrossRef]
143. Hu, X.; Hicks, C.W.; He, W.; Wong, P.; Macklin, W.B.; Trapp, B.D.; Yan, R. Bace1 modulates myelination in
the central and peripheral nervous system. Nat. Neurosci. 2006, 9, 1520–1525. [CrossRef] [PubMed]
Cells 2020, 9, 1574 21 of 23
144. Laird, F.M.; Cai, H.; Savonenko, A.V.; Farah, M.H.; He, K.; Melnikova, T.; Wen, H.; Chiang, H.C.; Xu, G.;
Koliatsos, V.E.; et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta
amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 2005, 25,
11693–11709. [CrossRef] [PubMed]
145. Querfurth, H.W.; LaFerla, F.M. Alzheimer’s disease. N. Engl. J. Med. 2010, 362, 329–344. [CrossRef] [PubMed]
146. Faghihi, M.A.; Modarresi, F.; Khalil, A.M.; Wood, D.E.; Sahagan, B.G.; Morgan, T.E.; Finch, C.E.; St Laurent, G.;
Kenny, P.J.; Wahlestedt, C. Expression of a noncoding RNA is elevated in Alzheimer’s disease and drives
rapid feed-forward regulation of beta-secretase. Nat. Med. 2008, 14, 723–730. [CrossRef]
147. da Rocha, S.T.; Heard, E. Novel players in X inactivation: Insights into Xist-mediated gene silencing and
chromosome conformation. Nat. Struct. Mol. Biol. 2017, 24, 197–204. [CrossRef]
148. Yu, Y.; Wang, Y.; Xiao, X.; Cheng, W.; Hu, L.; Yao, W.; Qian, Z.; Wu, W. MiR-204 inhibits hepatocellular cancer
drug resistance and metastasis through targeting NUAK1. Biochem. Cell Biol. 2019, 97, 563–570. [CrossRef]
149. Li, T.; Pan, H.; Li, R. The dual regulatory role of miR-204 in cancer. Tumour Biol. 2016, 37, 11667–11677.
[CrossRef]
150. Coolen, M.; Thieffry, D.; Drivenes, Ø.; Becker, T.S.; Bally-Cuif, L. miR-9 controls the timing of neurogenesis
through the direct inhibition of antagonistic factors. Dev. Cell 2012, 22, 1052–1064. [CrossRef]
151. Nissan, X.; Blondel, S.; Navarro, C.; Maury, Y.; Denis, C.; Girard, M.; Martinat, C.; De Sandre-Giovannoli, A.;
Levy, N.; Peschanski, M. Unique preservation of neural cells in Hutchinson- Gilford progeria syndrome is
due to the expression of the neural-specific miR-9 microRNA. Cell Rep. 2012, 2, 1–9. [CrossRef]
152. Hermeking, H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010, 17, 193–199. [CrossRef]
153. Provost, P. Interpretation and applicability of microRNA data to the context of Alzheimer’s and age-related
diseases. Aging 2010, 2, 166–169. [CrossRef] [PubMed]
154. Arancio, W.; Giordano, C.; Pizzolanti, G. A ceRNA analysis on LMNA gene focusing on the Hutchinson-
Gilford progeria syndrome. J. Clin. Bioinf. 2013, 3, 2. [CrossRef] [PubMed]
155. Arancio, W.; Genovese, S.I.; Bongiovanni, L.; Tripodo, C. A ceRNA approach may unveil unexpected
contributors to deletion syndromes, the model of 5q- syndrome. Oncoscience 2015, 2, 872–879. [CrossRef]
156. Zha, F.; Qu, X.; Tang, B.; Li, J.; Wang, Y.; Zheng, P.; Ji, T.; Zhu, C.; Bai, S. Long non-coding RNA MEG3
promotes fibrosis and inflammatory response in diabetic nephropathy via miR-181a/Egr-1/TLR4 axis. Aging
2019, 11, 3716–3730. [CrossRef] [PubMed]
157. Lin, Z.; Ge, J.; Wang, Z.; Ren, J.; Wang, X.; Xiong, H.; Gao, J.; Zhang, Y.; Zhang, Q. Let-7e modulates the
inflammatory response in vascular endothelial cells through ceRNA crosstalk. Sci. Rep. 2017, 7, 42498.
[CrossRef]
158. Huang, B.; Yu, H.; Li, Y.; Zhang, W.; Liu, X. Upregulation of long noncoding TNFSF10 contributes to
osteoarthritis progression through the miR-376-3p/FGFR1 axis. J. Cell. Biochem. 2019, 120, 19610–19620.
[CrossRef] [PubMed]
159. Liu, Y.; Lin, L.; Zou, R.; Wen, C.; Wang, Z.; Lin, F. MSC-derived exosomes promote proliferation and inhibit
apoptosis of chondrocytes via lncRNA-KLF3-AS1/miR-206/GIT1 axis in osteoarthritis. Cell Cycle 2018,
17, 2411–2422. [CrossRef]
160. Han, Y.; Wang, F.; Shao, L.; Huang, P.; Xu, Y. LncRNA TUG1 mediates lipopolysaccharide-induced
proliferative inhibition and apoptosis of human periodontal ligament cells by sponging miR-132.
Acta Biochim. Biophys. Sin. 2019, 51, 1208–1215. [CrossRef]
161. Li, S.; Liu, X.; Li, H.; Pan, H.; Acharya, A.; Deng, Y.; Yu, Y.; Haak, R.; Schmidt, J.; Schmalz, G.; et al.
Integrated analysis of long noncoding RNA-associated competing endogenous RNA network in periodontitis.
J. Periodont. Res. 2018, 53, 495–505. [CrossRef]
162. Zhu, J.; Zhang, X.; Gao, W.; Hu, H.; Wang, X.; Hao, D. lncRNA circRNA miRNA mRNA ceRNA network in
lumbar intervertebral disc degeneration. Mol. Med. Rep. 2019, 20, 3160–3174. [CrossRef]
163. Nie, L.; Zhang, P.; Wang, Q.; Zhou, X.; Wang, Q. lncRNA-Triggered Macrophage Inflammaging Deteriorates
Age-Related Diseases. Mediat. Inflamm. 2019, 2019, 4260309. [CrossRef] [PubMed]
164. Gao, B.; Zhang, X.; Huang, Y.; Yang, Z.; Zhang, Y.; Zhang, W.; Gao, Z.H.; Xue, D. Coding and non-coding
gene regulatory networks underlie the immune response in liver cirrhosis. PLoS ONE 2017, 12, e0174142.
[CrossRef] [PubMed]
Cells 2020, 9, 1574 22 of 23
165. Zhang, Y.; Zhang, H.; An, M.; Zhao, B.; Ding, H.; Zhang, Z.; He, Y.; Shang, H.; Han, X. Crosstalk in competing
endogenous RNA networks reveals new circular RNAs involved in the pathogenesis of early HIV infection.
J. Transl. Med. 2018, 16, 332. [CrossRef]
166. Jiang, H.; Ma, R.; Zou, S.; Wang, Y.; Li, Z.; Li, W. Reconstruction and analysis of the lncRNA-miRNA-mRNA
network based on competitive endogenous RNA reveal functional lncRNAs in rheumatoid arthritis.
Mol. Biosyst. 2017, 13, 1182–1192. [CrossRef] [PubMed]
167. Yan, S.; Wang, P.; Wang, J.; Yang, J.; Lu, H.; Jin, C.; Cheng, M.; Xu, D. Long Non-coding RNA HIX003209
Promotes Inflammation by Sponging miR-6089 via TLR4/NF-kB Signaling Pathway in Rheumatoid Arthritis.
Front. Immunol. 2019, 10, 2218. [CrossRef]
168. Paci, P.; Colombo, T.; Farina, L. Computational analysis identifies a sponge interaction network between
long non-coding RNAs and messenger RNAs in human breast cancer. BMC Syst. Biol. 2014, 8, 83. [CrossRef]
169. Tiansheng, G.; Junming, H.; Xiaoyun, W.; Peixi, C.; Shaoshan, D.; Qianping, C. lncRNA Metastasis-Associated
Lung Adenocarcinoma Transcript 1 Promotes Proliferation and Invasion of Non-Small Cell Lung Cancer
Cells via Down-Regulating miR-202 Expression. Cell J. 2020, 22, 375–385.
170. Xu, X.W.; Zheng, B.A.; Hu, Z.M.; Qian, Z.Y.; Huang, C.J.; Liu, X.Q.; Wu, W.D. Circular RNA hsa-circ-000984
promotes colon cancer growth and metastasis by sponging miR-106b. Oncotarget 2017, 8, 91674–91683.
[CrossRef]
171. Zhong, Z.; Huang, M.; Lv, M.; He, Y.; Duan, C.; Zhang, L.; Chen, J. Circular RNA MYLK as a competing
endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling
pathway. Cancer Lett. 2017, 403, 305–317. [CrossRef]
172. Hajjari, M.; Salavaty, A. HOTAIR: An oncogenic long non-coding RNA in different cancers. Cancer Biol. Med.
2015, 12, 1–9.
173. Nie, Y.; Liu, X.; Qu, S.; Song, E.; Zou, H.; Gong, C. Long non-coding RNA HOTAIR is an independent
prognostic marker for nasopharyngeal carcinoma progression and survival. Cancer Sci. 2013, 104, 458–464.
[CrossRef] [PubMed]
174. Rinn, J.L.; Kertesz, M.; Wang, J.K.; Squazzo, S.L.; Xu, X.; Brugmann, S.A.; Goodnough, L.H.; Helms, J.A.;
Farnham, P.J.; Segal, E.; et al. Functional demarcation of active and silent chromatin domains in human HOX
loci by noncoding RNAs. Cell 2007, 129, 1311–1323. [CrossRef] [PubMed]
175. Deng, J.; Yang, M.; Jiang, R.; An, N.; Wang, X.; Liu, B. Long Non-Coding RNA HOTAIR Regulates the
Proliferation, Self-Renewal Capacity, Tumor Formation and Migration of the Cancer Stem-Like Cell (CSC)
Subpopulation Enriched from Breast Cancer Cells. PLoS ONE 2017, 12, e0170860. [CrossRef] [PubMed]
176. Lou, W.; Ding, B.; Fu, P. Pseudogene-Derived lncRNAs and Their miRNA Sponging Mechanism in Human
Cancer. Front. Cell Dev. Biol. 2020, 8, 85. [CrossRef] [PubMed]
177. Li, L.; Wang, D.; Xue, M.; Mi, X.; Liang, Y.; Wang, P. 3’UTR shortening identifies high-risk cancers with
targeted dysregulation of the ceRNA network. Sci. Rep. 2014, 4, 5406. [CrossRef] [PubMed]
178. Sanchez-Mejias, A.; Tay, Y. Competing endogenous RNA networks: Tying the essential knots for cancer
biology and therapeutics. J. Hematol. Oncol. 2015, 8, 30. [CrossRef] [PubMed]
179. Naorem, L.D.; Prakash, V.S.; Muthaiyan, M.; Venkatesan, A. Comprehensive analysis of dysregulated
lncRNAs and their competing endogenous RNA network in triple-negative breast cancer. Int. J.
Biol. Macromol. 2020, 145, 429–436. [CrossRef] [PubMed]
180. Yang, R.; Xing, L.; Wang, M.; Chi, H.; Zhang, L.; Chen, J. Comprehensive Analysis of Differentially
Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative
Breast Cancer. Cell. Physiol. Biochem. 2018, 50, 473–488. [CrossRef]
181. Tian, W.; Jiang, C.; Huang, Z.; Xu, D.; Zheng, S. Comprehensive analysis of dysregulated lncRNAs,
miRNAs and mRNAs with associated ceRNA network in esophageal squamous cell carcinoma. Gene 2019,
696, 206–218. [CrossRef]
182. Wang, X.; Hu, K.B.; Zhang, Y.Q.; Yang, C.J.; Yao, H.H. Comprehensive analysis of aberrantly expressed
profiles of lncRNAs, miRNAs and mRNAs with associated ceRNA network in cholangiocarcinoma.
Cancer Biomark 2018, 23, 549–559. [CrossRef]
183. Wang, H.; Niu, L.; Jiang, S.; Zhai, J.; Wang, P.; Kong, F.; Jin, X. Comprehensive analysis of aberrantly expressed
profiles of lncRNAs and miRNAs with associated ceRNA network in muscle-invasive bladder cancer.
Oncotarget 2016, 7, 86174–86185. [CrossRef] [PubMed]
Cells 2020, 9, 1574 23 of 23
184. Arun, K.; Arunkumar, G.; Bennet, D.; Chandramohan, S.M.; Murugan, A.K.; Munirajan, A.K. Comprehensive
analysis of aberrantly expressed lncRNAs and construction of ceRNA network in gastric cancer. Oncotarget
2018, 9, 18386–18399. [CrossRef] [PubMed]
185. Hoadley, K.A.; Yau, C.; Hinoue, T.; Wolf, D.M.; Lazar, A.J.; Drill, E.; Shen, R.; Taylor, A.M.; Cherniack, A.D.;
Thorsson, V.; et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33
Types of Cancer. Cell 2018, 173, 291–304. [CrossRef]
186. Zhang, X.; Zhang, W.; Jiang, Y.; Liu, K.; Ran, L.; Song, F. Identification of functional lncRNAs in gastric
cancer by integrative analysis of GEO and TCGA data. J. Cell. Biochem. 2019, 120, 17898–17911. [CrossRef]
[PubMed]
187. Li, Z.; Jiang, C.; Yuan, Y. TCGA based integrated genomic analyses of ceRNA network and novel subtypes
revealing potential biomarkers for the prognosis and target therapy of tongue squamous cell carcinoma.
PLoS ONE 2019, 14, e0216834. [CrossRef]
188. Li, Y.; Gu, J.; Xu, F.; Zhu, Q.; Ge, D.; Lu, C. Transcriptomic and functional network features of lung squamous
cell carcinoma through integrative analysis of GEO and TCGA data. Sci. Rep. 2018, 8, 15834. [CrossRef]
189. Wang, W.; Zhuang, Q.; Ji, K.; Wen, B.; Lin, P.; Zhao, Y.; Li, W.; Yan, C. Identification of miRNA, lncRNA
and mRNA-associated ceRNA networks and potential biomarker for MELAS with mitochondrial DNA
A3243G mutation. Sci. Rep. 2017, 7, 41639. [CrossRef]
190. Zhu, Z.; Hou, Q.; Li, M.; Fu, X. Molecular mechanism of myofibroblast formation and strategies for clinical
drugs treatments in hypertrophic scars. J. Cell. Physiol. 2020, 235, 4109–4119. [CrossRef]
191. Fan, C.N.; Ma, L.; Liu, N. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA
network identifies four-lncRNA signature as a prognostic biomarker for breast cancer. J. Transl. Med. 2018,
16, 264. [CrossRef]
192. Ye, G.; Guo, L.; Xing, Y.; Sun, W.; Yuan, M. Identification of prognostic biomarkers of prostate cancer with
long non-coding RNA-mediated competitive endogenous RNA network. Exp. Ther. Med. 2019, 17, 3035–3040.
[CrossRef]
193. Xiong, D.D.; Dang, Y.W.; Lin, P.; Wen, D.Y.; He, R.Q.; Luo, D.Z.; Feng, Z.B.; Chen, G. A circRNA-miRNA-
mRNA network identification for exploring underlying pathogenesis and therapy strategy of hepatocellular
carcinoma. J. Transl. Med. 2018, 16, 220. [CrossRef] [PubMed]
194. Zhou, M.; Diao, Z.; Yue, X.; Chen, Y.; Zhao, H.; Cheng, L.; Sun, J. Construction and analysis of dysregulated
lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human
pancreatic cancer. Oncotarget 2016, 7, 56383–56394. [CrossRef] [PubMed]
195. Smillie, C.L.; Sirey, T.; Ponting, C.P. Complexities of post-transcriptional regulation and the modeling of
ceRNA crosstalk. Crit. Rev. Biochem. Mol. Biol. 2018, 53, 231–245. [CrossRef] [PubMed]
196. Fiscon, G.; Conte, F.; Farina, L.; Paci, P. Network-Based Approaches to Explore Complex Biological Systems
towards Network Medicine. Genes 2018, 9, 437. [CrossRef]
197. Zhang, Z.; He, T.; Huang, L.; Ouyang, Y.; Li, J.; Huang, Y.; Wang, P.; Ding, J. Two precision
medicine predictive tools for six malignant solid tumors: From gene-based research to clinical application.
J. Transl. Med. 2019, 17, 405. [CrossRef]
198. Sun, C.; Huang, L.; Li, Z.; Leng, K.; Xu, Y.; Jiang, X.; Cui, Y. Long non-coding RNA MIAT in development
and disease: A new player in an old game. J. Biomed. Sci. 2018, 25, 23. [CrossRef]
199. Yang, Y.; Zhang, Z.; Wu, Z.; Lin, W.; Yu, M. Downregulation of the expression of the lncRNA MIAT
inhibits melanoma migration and invasion through the PI3K/AKT signaling pathway. Cancer Biomark 2019,
24, 203–211. [CrossRef]
200. Zhang, W.; Chen, Q.; Lei, C. lncRNA MIAT promotes cell invasion and migration in esophageal cancer.
Exp. Ther. Med. 2020, 19, 3267–3274. [CrossRef]
201. Xu, H.; Zhou, J.; Tang, J.; Min, X.; Yi, T.; Zhao, J.; Ren, Y. Identification of serum exosomal lncRNA MIAT as a
novel diagnostic and prognostic biomarker for gastric cancer. J. Clin. Lab. Anal. 2020, 2020, e23323. [CrossRef]
c© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
